Document:

<PAGE>

                                                         [Letterhead of Telstra]

                                                         Ziggy Switkowski
                                                         Chief Executive Officer

     22 February 2002

     Mr Ted Pretty
     Group Managing Director
     Telstra Retail
     Level 4, 400 George Street
     SYDNEY NSW 2000

     Dear Ted

     I am very pleased to confirm the offer to you of the following revised
     terms of employment with Telstra Corporation Limited ('Telstra'). The
     success of Telstra and its related companies depends very much on our
     senior team and I am sure that you will continue to enjoy contributing to
     and being a part of Telstra's success.

     This Agreement, together with any attachments, sets out the terms and
     conditions of your employment and is made under the laws of New South
     Wales. Please indicate your acceptance of the terms and conditions outlined
     in this letter of offer by signing the duplicate copy on each page and
     returning it to me as soon as possible.

1    INDIVIDUAL EMPLOYMENT

     1.1    This Agreement represents a direct relationship between me, on
            behalf of Telstra, and yourself and as such involves mutual
            obligations.

     1.2    In offering this Agreement, Telstra and I undertake to behave in
            ways worthy of your respect and trust. You will be given a clear
            understanding of the purpose of your role and any relevant critical
            issues. As your manager I will seek your contribution and listen to
            your views. You will know what is required of you in terms of both
            results and behaviour and will be remunerated and rewarded fairly
            based on your performance.

     1.3    In accepting this Agreement you undertake to do any work within your
            skills and ability. You agree to work flexibly and participate in
            continuous improvement of work practices and systems. You are
            prepared to be accountable for your performance.

/s/                                                    /s/
-------------------------            Page 1            -------------------------
(signatory initials)                                        (signatory initials)

--------------------------------------------------------------------------------
242 Exhibition Street Melbourne Vic 3000   231 Elizabeth Street Sydney NSW 2000
Australia                                  Australia
Locked Bag 5639 Melbourne Vic 8100         Locked Bag 6600 Sydney NSW 1100
Telephone    (03) 9204 9999                Telephone    (02) 9204 9999
Facsimile    (03) 9632 3336                Facsimile    (02) 9264 2044

                                                     Telstra Corporation Limited
                                                     ACN 051 775 556

<PAGE>

2    ENGAGEMENT

     2.1    The commencement date of your employment under this Agreement is 1
            January 2002 and will be reviewed by 31 December 2006.

     2.2    The relevant date for the purposes of annual leave accruals and long
            service leave will be your original commencement date.

     2.3    You will initially be assigned to the role of Group Managing
            Director, Telstra Retail reporting to myself as Chief Executive
            Officer. The reporting requirements of this role may be varied from
            time to time in accordance with the needs of Telstra.

3    LOCATION

     3.1    You will initially be located in the Sydney office in New South
            Wales.

     3.2    In the event you agree to move residence to perform a role, Telstra
            will provide you with relocation assistance in accordance with the
            applicable Telstra policy, as varied from time to time.

4    RE-ASSIGNMENT

     4.1    Telstra may re-assign you at any time to an equivalent role for
            which Telstra judges you to be suitably qualified and experienced,
            either within Telstra or on secondment to any related company.

     4.2    Unless otherwise agreed in writing, your assignment (or subsequent
            re-assignment) within Telstra, its related bodies corporate or other
            specified entities will continue on the terms and conditions of this
            Agreement. Any re-assignment will not constitute termination of this
            Agreement or your employment with Telstra.

5    HOURS OF WORK

            Hours of work will be normal business hours and such further hours
            reasonably necessary to do the job.

6    PERFORMANCE

     6.1    You are required to perform your role in a proper and efficient
            manner. You are to devote your time, attention and energy to the
            performance of your duties and use your best endeavours to promote
            and enhance the interests of Telstra or business to which you have
            been assigned pursuant to this Agreement. Your performance will be
            regularly reviewed and discussed with you under Telstra's
            performance review process.

     6.2    Except with the written consent of Telstra you must not undertake,
            be employed in connection with or have any interest in any other
            business or profession during your employment under this Agreement,
            other than by way of holding any shares or other securities which
            are publicly listed or in a private family company or otherwise
            available to the general public by way of investment.

/s/                                                    /s/
-------------------------            Page 2            -------------------------
(signatory initials)                                        (signatory initials)

<PAGE>

7    REMUNERATION

     7.1    Your remuneration has fixed and variable elements which make up your
            Total Remuneration.

     7.2    Fixed Remuneration includes salary and superannuation and any
            benefits (which also may include fringe benefit tax). Your Fixed
            Remuneration for the term of this Agreement will be $1,000,000 per
            annum.

     7.3    You will participate in the Manager Incentive Plan (as amended or
            replaced from time to time) commencing in financial year 2002/2003,
            which will represent the variable element of your Total
            Remuneration. Any payment due to you from this plan will be paid at
            the end of each remuneration year.

     7.4    Two Remuneration Summaries are attached. Remuneration Summary A.
            outlines your Total Remuneration for the period 1 January 2002 to 30
            June 2002. Remuneration Summary B. outlines your Total Remuneration
            for the period 1 July 2002 to 31 December 2006.

     7.5    The following retention payments shall be payable based on completed
            service with the Company. Provided you remain employed by Telstra on
            the dates below, you will be paid the specified amounts within 30
            days of these dates:

                                          Amount
                  Qualifying Date        Payable
                  30 June 2002          $ 200,000
                  1 July 2002           $ 220,000
                  1 July 2003           $ 240,000
                  1 July 2004           $ 260,000
                  1 July 2005           $ 280,000
                  1 July 2006           $ 300,000

8    SUPERANNUATION

            A company superannuation benefit is included in your Fixed
            Remuneration. At all times you must allocate at least the minimum
            Superannuation Guarantee (as varied from time to time) to a
            complying superannuation scheme in accordance with Telstra policy.
            Additional superannuation contributions above this amount can be
            paid from your Total Remuneration, subject to statutory limits.

9    LEAVE

     9.1    You will accrue 4 weeks leave annually, to be taken in accordance
            with Telstra policy, at a time agreed between you and your manager.

     9.2    Long service leave will accrue and be paid in accordance with
            Telstra policy. Currently, Telstra policy provides for three months
            long service leave after ten years employment with Telstra.

     9.3    Sick leave will be by agreement with your manager. The provision of
            sick leave is based on ensuring that all employees receive adequate
            paid leave when they are unable to attend work as a result of
            illness.

/s/                                                    /s/
-------------------------            Page 3            -------------------------
(signatory initials)                                        (signatory initials)

<PAGE>

10   SPECIAL LEAVE

     10.1   For financial years 2002/2003 and 2003/2004, it is agreed that
            special paid leave for personal reasons will be available to you.
            The scheduling of this leave will be in agreement with the CEO and
            will be for a maximum period of 5 weeks in each of the above
            financial years. This leave will lapse if it is not taken during the
            above periods.

11   TERMINATION OF YOUR EMPLOYMENT

     11.1   Subject to relevant legislation, your employment may be terminated
            by either party giving not less than six months written notice to
            the other party.

     11.2   If Telstra terminates your employment on notice, you may be required
            to remain in Telstra's service for all or part of the notice period
            or be paid at the Fixed Remuneration rate in lieu of notice.

     11.3   Telstra may terminate your employment summarily if you commit any
            act of serious misconduct. In the event of such termination you will
            be entitled only to Fixed Remuneration to the date of termination.

     11.4   If Telstra terminates your employment due to redundancy, you will
            receive, in addition to any notice or payment in lieu of notice, a
            severance payment determined in accordance with Telstra policy.
            Should this severance payment be less than the termination payment
            provided for in clause 11.5, the termination payment provided for in
            clause 11.5 will apply.

     11.5   If Telstra terminates your employment for any reason other than
            serious misconduct or redundancy, you will receive in addition to
            any notice or payment in lieu of notice a termination payment
            equivalent to twelve months Fixed Remuneration.

     11.6   If your employment ceases for whatever reason, Telstra may offset
            any amounts owing by you to Telstra (or its related bodies corporate
            or other specified entities) against any amounts otherwise payable
            to you upon termination.

12   TRAVEL AND BUSINESS RELATED EXPENSES

            You may be required to undertake business related travel at
            Telstra's expense or at the expense of your assigned business. In
            such circumstances you will receive reimbursement of business
            expenses reasonably and actually incurred and verified in accordance
            with Telstra's Travel Policy or if relevant your assigned business
            Travel Policy.

13   CONFIDENTIALITY

     13.1   In entering this Agreement you agree and undertake:

            (a)   to maintain the confidentiality of the contents of this
                  Agreement, except as may be necessary for the administration
                  of your employment and financial affairs; and

            (b)   that at all times during and after your employment under this
                  Agreement you will keep confidential and not disclose any
                  Confidential Information to any person other than in the
                  performance of your duties, as required by law or with the
                  prior written consent of Telstra; and

            (c)   that you will not at any time during or after your employment
                  under this Agreement use any Confidential Information for the
                  benefit of any person except where authorised to do so by
                  Telstra, its Related Bodies Corporate other specified
                  entities and;

/s/                                                    /s/
-------------------------            Page 4            -------------------------
(signatory initials)                                        (signatory initials)

<PAGE>

            (d)   that immediately upon the request of Telstra or upon the
                  termination of your employment with Telstra you will:

                  (i)   deliver to Telstra all Confidential Information which is
                        in your control and which is physically capable of
                        delivery; and

                  (ii)  destroy any Confidential Information which is stored in
                        any electronic, magnetic or optical form but which is
                        not capable of delivery to Telstra so that it cannot be
                        recovered or in any way reconstructed or reconstituted.

            These obligations shall lapse in relation to any of the Confidential
            information which comes into the public domain other than through
            your wrongful act.

     13.2   For the purposes of this Agreement:

            (a)   "Confidential Information" means any trade secret, technical
                  knowledge, concepts, ideas, designs, programs, processes,
                  procedures, innovations, inventions, data bases, data surveys,
                  customer lists or information, sales plans or marketing plans,
                  research, software, records or other information concerning
                  Telstra or its Related Bodies Corporate or any of their
                  customers or suppliers which is secret and confidential of
                  which you became aware during your employment with Telstra;
                  and

            (b)   "Related Body Corporate" has the same meaning as in Section 50
                  of the Corporations Law.

     13.3   It is a condition of your employment that you will be familiar with
            and comply with the protection of communications provisions in the
            Telecommunications Act 1997 (or its successor).

14   FUTURE EMPLOYMENT

            If your employment with Telstra ceases for any reason you must not
            (without the prior written consent of Telstra) be employed by, or
            provide services as an agent, independent contractor or in any other
            capacity to, any telecommunications business or any business of a
            like or similar nature to that conducted by Telstra, whether in
            Australia or overseas, for the minimum period of notice set out in
            clause 11.1 of this Agreement. This period will commence from the
            date that the notice period commences. Each element of this
            restraint operates to the extent to which it is deemed reasonable by
            any court. Part of the remuneration and benefits provided to you by
            Telstra is specifically referable to this obligation, and your
            agreement to this term is an acknowledgment that this term is
            reasonable and goes no further than is necessary to protect the
            interests and Confidential Information of Telstra and its Related
            Bodies Corporate.

/s/                                                    /s/
-------------------------            Page 5            -------------------------
(signatory initials)                                        (signatory initials)

<PAGE>

15   RETURN OF PROPERTY

            Upon termination of your employment with Telstra you must
            immediately return to Telstra, (or where on assignment to your
            assigned business) or its authorised representative, all property of
            Telstra (or property of the assigned business) which is in your
            possession custody or control, including any documents and papers
            and all copies of such documents and papers.

16   INDEMNITY

            In the event that you are appointed to a position of statutory
            responsibility and accountability in any company formed or acquired
            by Telstra, the Telstra Directors' and Officer Liability Policy will
            apply.

17   OTHER CONDITIONS OF EMPLOYMENT

            In entering this Agreement you agree that the policies, procedures,
            and processes of Telstra, as varied or added to from time to time,
            will apply to and govern your employment. These policies,
            procedures, and processes can be accessed via Telstra's Intranet. In
            addition, you must comply with the individual policies, procedures,
            and processes of the business to which you are assigned.

18   ENTIRE AGREEMENT

     18.1   This document together with any Attachments records the agreement
            between the parties. No previous negotiations, understandings,
            contracts, agreements, representations, warranties, memoranda or
            commitments will affect the terms and conditions of your employment
            by Telstra.

     18.2   No oral explanation or information provided by any party to another
            shall

            (a)   affect the meaning or interpretation of this document, or

            (b)   constitute any collateral agreement, warranty or understanding
                  between any of the parties.

     I would like to take this opportunity to congratulate you on your revised
     terms of employment and look forward to working closely with you.

     Yours sincerely

     /s/ Ziggy E Switkowski
     -----------------------
     Ziggy E Switkowski
     Chief Executive Officer

/s/                                                    /s/
-------------------------            Page 6            -------------------------
(signatory initials)                                        (signatory initials)

<PAGE>

     I confirm acceptance of the terms and conditions set out in this letter.

/s/ Ted Pretty                                          6/3/2002
-------------------------                              -------------------------
Name                                                   Date

/s/                                                    /s/
-------------------------            Page 7            -------------------------
(signatory initials)                                        (signatory initials)

<PAGE>

--------------------------------------------------------------------------------
                             Remuneration Summary A

Fixed Remuneration
   Fixed Remuneration /1/                                            $ 1,000,000
      Minimum Superannuation Amount        $                  8,804

Variable Remuneration
   2001/2002 Target Incentive              0% of Total Remuneration  $         0
   ("At Risk" Component)

Total Remuneration
   Total Potential Remuneration                                      $ 1,000,000
                                                                     -----------
   (including "On Target" Incentive Level)

   Name:             Ted Pretty
                     ----------------------------------------------
   Employee Number:  37133624
                     ----------------------------------------------
   Effective Date:   1 January 2002 to 30 June 2002
                     ----------------------------------------------

----------

/1/  Fixed Remuneration includes the Telstra compulsory superannuation guarantee
     contribution.

     By agreement, a greater part of your Fixed Remuneration can be paid as
     company superannuation contributions, subject to the total contribution
     (including the compulsory amount) not exceeding the statutory age-based
     deduction limits.

     If you are currently in an excess pension Reasonable Benefit Limit (RBL)
     position, Telstra may not be required to pay any part of your subject to
     the total as superannuation contributions. You should speak to a financial
     adviser if this situation applies to you.
--------------------------------------------------------------------------------

<PAGE>

--------------------------------------------------------------------------------
                             Remuneration Summary B

Fixed Remuneration
   Fixed Remuneration /1/                                            $ 1,000,000
      Minimum Superannuation Amount       $          8804 (indexed)

Variable Remuneration
   2002/2003 Target Incentive             35% of Total Remuneration  $   539,000
   ("At Risk" Component)

Total Remuneration
   Total Potential Remuneration                                      $ 1,539,000
   (including "On Target" Incentive Level)

   Name:             Ted Pretty
                     ----------------------------------------------
   Employee Number:  37133624
                     ----------------------------------------------
   Effective Date:   1 July 2002 to 31 December 2006
                     ----------------------------------------------

----------

/1/  Fixed Remuneration includes the Telstra compulsory superannuation guarantee
     contribution.

     By agreement, a greater part of your Fixed Remuneration can be paid as
     company superannuation contributions, subject to the total contribution
     (including the compulsory amount) not exceeding the statutory age-based
     deduction limits.

     If you are currently in an excess pension Reasonable Benefit Limit (RBL)
     position, Telstra may not be required to pay any part of your subject to
     the total as superannuation contributions. You should speak to a financial
     adviser if this situation applies to you.
--------------------------------------------------------------------------------

<PAGE>

--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------
                                                    Remuneration Summary B
-----------------------------------------------------------------------------------------------------------------------------
                                                      2002/03/1/      2003/04        2004/05        2005/06       2006/07/2/
-----------------------------------------------------------------------------------------------------------------------------
<S>                                                  <C>            <C>            <C>            <C>            <C>
Fixed Remuneration/3/                                $  1,000,000   $  1,000,000   $  1,000,000   $  1,000,000   $  1,000,000
 Minimum Superannuation Amount - $8804 pa (indexed)
-----------------------------------------------------------------------------------------------------------------------------
Variable - assuming on target results                $    539,000   $    539,000   $    539,000   $    539,000   $    539,000
 "At Risk" Component
-----------------------------------------------------------------------------------------------------------------------------
Retention Payments                                   $    220,000   $    240,000   $    260,000   $    280,000   $    300,000
 Paid annual on 1 July
-----------------------------------------------------------------------------------------------------------------------------
Total Potential Cash Remuneration at Target          $  1,759,000   $  1,779,000   $  1,799,000   $  1,819,000   $  1,839,000
-----------------------------------------------------------------------------------------------------------------------------
<FN>
<F1>
/1/ MIP commences from 1 July 2002 for the 2002/03 financial year

<F2>
/2/ Arrangements to be reviewed 31 Dec 2006

     Name:              Ted Pretty
                        ----------------------------------------------
     Employee Number:   37133624
                        ----------------------------------------------
     Effective Date:    1 July 2002 to 31 December 2006
                        ----------------------------------------------

<F3>
/3/ Fixed Remuneration includes the Telstra compulsory superannuation guarantee
contribution.

By agreement, a greater part of your Fixed Remuneration can be paid as company
superannuation contributions, subject to the total contribution (including the
compulsory amount) not exceeding the statutory age-based deduction limits.

If you are currently in an excess pension Reasonable Benefit Limit (RBL)
position, Telstra may not be required to pay any part of your subject to the
total as superannuation contributions. You should speak to a financial adviser
if this situation applies to you.
--------------------------------------------------------------------------------
</FN>
</TABLE>MERGER AGREEMENT AND PLAN OF REORGANIZATION

 EXHIBIT 10.1 
  
 MERGER AGREEMENT AND PLAN OF REORGANIZATION 
  
 BY AND AMONG 
  
 PAINCARE HOLDINGS, INC., 
  
 PAINCARE ACQUISITION COMPANY VI, INC., 
  
 SPINE AND PAIN CENTER, INC. 
  
 AND 
  
 MICHAEL P. MARTIRE, M.D. 
  
 EXECUTION DATE: DECEMBER 23, 2003. 

	 1.
	 	 DEFINITIONS.
	  	2
			
	 2.
	 	 TRANSACTION.
	  	2
				
	 	 	2.1	 	 Transaction.
	  	2
				
	 	 	2.2	 	 Effect of the Merger.
	  	2
				
	 	 	2.3	 	 Effective Time; Filing of Certificates of Merger.
	  	2
				
	 	 	2.4	 	 Articles of Incorporation.
	  	2
				
	 	 	2.5	 	 Bylaws.
	  	2
				
	 	 	2.6	 	 Directors and Officers.
	  	2
				
	 	 	2.7	 	 Tax Consequences.
	  	3
				
	 	 	2.8	 	 Additional Actions.
	  	3
				
	 	 	2.9	 	 No Dissenters’ Rights.
	  	3
				
	 	 	2.10	 	 Surrender of Certificates.
	  	3
				
	 	 	 	 	 (a)    Company’s Shares.
	  	3
				
	 	 	 	 	 (b)    Dividends.
	  	3
				
	 	 	2.11	 	 Medical Assets.
	  	3
				
	 	 	2.12	 	 Conversion of Shares.
	  	4
				
	 	 	2.13	 	 Shareholder Consent and Release.
	  	4
				
	 	 	2.14	 	 Piggyback Registration.
	  	4
				
	 	 	2.15	 	 Shareholder’s Obligation to Furnish Information.
	  	5
				
	 	 	2.16	 	 Suspension of Sales Pending Amendment to Prospectus.
	  	5
				
	 	 	2.17	 	 Registration Expenses.
	  	6
			
	 3.
	 	 TRANSACTION CONSIDERATION.
	  	6
				
	 	 	3.1	 	 Merger Consideration.
	  	6
				
	 	 	3.2	 	 Intentionally Omitted.
	  	7
				
	 	 	3.3	 	 Closing Date Adjustments
	  	7
				
	 	 	 	 	 (a)    Transaction Related Adjustment.
	  	7
				
	 	 	 	 	 (b)    Financial Statements.
	  	7
				
	 	 	 	 	 (c)    Closing Date Balance Sheet.
	  	7
				
	 	 	3.4	 	 Earnout Payment.
	  	8
				
	 	 	 	 	 (a)    General.
	  	8

  

 i 

					
	 	  	 	  	 (b)
	 	 Installment Payment Discount.
	  	8
					
	 	  	 	  	 (c)
	 	 Installment Payment Premium.
	  	8
					
	 	  	 	  	 (d)
	 	 Manner of Payment.
	  	9
					
	 	  	 	  	 (e)
	 	 Earnout Cap.
	  	9
					
	 	  	 	  	 (f)
	 	 Definitions for Purposes of Section 3.4.
	  	9
					
	 	  	 	  	 (g)
	 	 Adjustments to Installment Payments.
	  	11
				
	 	  	3.5	  	 Intentionally Omitted.
	  	11
			
	 4.
	  	 REPRESENTATIONS AND WARRANTIES OF THE SHAREHOLDER.
	  	11
				
	 	  	4.1	  	 Organization, Qualification, and Corporate Power.
	  	11
				
	 	  	4.2	  	 Capitalization.
	  	11
				
	 	  	4.3	  	 Authorization.
	  	12
				
	 	  	4.4	  	 Noncontravention.
	  	12
				
	 	  	4.5	  	 Broker’s Fees.
	  	12
				
	 	  	4.6	  	 Title to Assets.
	  	12
				
	 	  	4.7	  	 No Subsidiaries.
	  	13
				
	 	  	4.8	  	 Financial Statements.
	  	13
				
	 	  	4.9	  	 Events Subsequent to Most Recent Year End.
	  	13
					
	 	  	 	  	 (a)
	 	 Sale or Lease of Assets.
	  	13
					
	 	  	 	  	 (b)
	 	 Contracts.
	  	13
					
	 	  	 	  	 (c)
	 	 Change in Contracts.
	  	13
					
	 	  	 	  	 (d)
	 	 Security Interests.
	  	13
					
	 	  	 	  	 (e)
	 	 Investments.
	  	13
					
	 	  	 	  	 (f)
	 	 Debts.
	  	14
					
	 	  	 	  	 (g)
	 	 Liabilities Unaffected.
	  	14
					
	 	  	 	  	 (h)
	 	 Claims Unaffected.
	  	14
					
	 	  	 	  	 (i)
	 	 Articles and Bylaws.
	  	14
					
	 	  	 	  	 (j)
	 	 Changes in Equity.
	  	14
					
	 	  	 	  	 (k)
	 	 Distribution.
	  	14
					
	 	  	 	  	 (l)
	 	 Property Damage.
	  	14
					
	 	  	 	  	 (m)
	 	 Transactions with Affiliates.
	  	14

  

 ii 

				
	 	  	 (n)
	 	 Collective Bargaining Agreements.
	  	14
				
	 	  	 (o)
	 	 Compensation Changes.
	  	14
				
	 	  	 (p)
	 	 Employee Benefit Plans.
	  	14
				
	 	  	 (q)
	 	 Officers; Directors; Employees.
	  	14
				
	 	  	 (r)
	 	 Charitable or Capital Contributions.
	  	15
				
	 	  	 (s)
	 	 Ordinary Course of Business.
	  	15
				
	 	  	 (t)
	 	 Accounting Practices.
	  	15
				
	 	  	 (u)
	 	 Accounts Receivable.
	  	15
				
	 	  	 (v)
	 	 In General.
	  	15
			
	 4.10
	  	 Undisclosed Liabilities.
	  	15
			
	 4.11
	  	 Tax Matters.
	  	15
				
	 	  	 (a)
	 	 Tax Returns.
	  	15
				
	 	  	 (b)
	 	 Withholding.
	  	15
				
	 	  	 (c)
	 	 No Disputes of Claims.
	  	16
				
	 	  	 (d)
	 	 No Waivers.
	  	16
				
	 	  	 (e)
	 	 No Special Circumstances.
	  	16
				
	 	  	 (f)
	 	 Subchapter “S”.
	  	16
				
	 	  	 (g)
	 	 Audits of Tax Returns.
	  	16
				
	 	  	 (h)
	 	 Period of Assessment.
	  	16
				
	 	  	 (i)
	 	 Tax Agreements.
	  	17
				
	 	  	 (j)
	 	 Inclusions in Taxable Periods.
	  	17
				
	 	  	 (k)
	 	 Consents.
	  	17
				
	 	  	 (l)
	 	 Personal Holding Company
	  	17
				
	 	  	 (m)
	 	 Consolidated Tax Returns.
	  	17
			
	 4.12
	  	 Real Property.
	  	17
				
	 	  	 (a)
	 	 Binding.
	  	17
				
	 	  	 (b)
	 	 Continued Validity.
	  	17
				
	 	  	 (c)
	 	 No Defaults.
	  	17
				
	 	  	 (d)
	 	 Repudiation.
	  	17
				
	 	  	 (e)
	 	 No Disputes.
	  	17

  

 iii 

	 	 	 (f)
	  	 Subleases.
	  	18
				
	 	 	 (g)
	  	 Encumbrances.
	  	18
				
	 	 	 (h)
	  	 Approvals.
	  	18
				
	 	 	 (i)
	  	 Utilities.
	  	18
			
	 4.13
	 	 Intellectual Property.
	  	18
			
	 4.14
	 	 Condition of Tangible Assets.
	  	18
			
	 4.15
	 	 Contracts.
	  	18
				
	 	 	 (a)
	  	 Personal Property Leases.
	  	18
				
	 	 	 (b)
	  	 Services.
	  	18
				
	 	 	 (c)
	  	 Partnership; Joint Venture.
	  	18
				
	 	 	 (d)
	  	 Indebtedness.
	  	18
				
	 	 	 (e)
	  	 Confidentiality; Non-Competition.
	  	19
				
	 	 	 (f)
	  	 Shareholders’ Agreements.
	  	19
				
	 	 	 (g)
	  	 Plans.
	  	19
				
	 	 	 (h)
	  	 Employment or Consulting Agreements.
	  	19
				
	 	 	 (i)
	  	 Advances; Loans.
	  	19
				
	 	 	 (j)
	  	 Adverse Effects.
	  	19
				
	 	 	 (k)
	  	 Other Agreements.
	  	19
			
	 4.16
	 	 Powers of Attorney.
	  	19
			
	 4.17
	 	 Insurance; Malpractice.
	  	19
			
	 4.18
	 	 Litigation.
	  	20
			
	 4.19
	 	 Health Care Compliance.
	  	21
			
	 4.20
	 	 Fraud and Abuse.
	  	21
			
	 4.21
	 	 Legal Compliance.
	  	21
			
	 4.22
	 	 Rates and Reimbursement Policies.
	  	22
			
	 4.23
	 	 Medical Staff.
	  	22
			
	 4.24
	 	 Employees.
	  	22
			
	 4.25
	 	 Employee Benefits.
	  	23
				
	 	 	 (a)
	  	 Plans.
	  	23
				
	 	 	 (b)
	  	 Compliance.
	  	23

  

 iv 

	 	  	(c	)	 	 Reports and Descriptions.
	  	23
				
	 	  	(d	)	 	 Contributions.
	  	23
				
	 	  	(e	)	 	 Qualified Plan.
	  	23
				
	 	  	(f	)	 	 Market Value.
	  	23
				
	 	  	(g	)	 	 Copies.
	  	23
				
	 	  	(h	)	 	 Maintenance of Plans.
	  	24
			
	 (i)
	  	 Reportable Events
	  	24
			
	 (ii)
	  	 Prohibited Transactions
	  	24
			
	 4.26
	  	 Physicians and Other Providers.
	  	24
				
	 	  	(a	)	 	 Licenses.
	  	24
				
	 	  	(b	)	 	 Controlled Substances.
	  	24
				
	 	  	(c	)	 	 Actions.
	  	24
			
	 (i)
	  	 Malpractice Actions
	  	24
			
	 (ii)
	  	 Disciplinary Proceedings
	  	24
			
	 (iii)
	  	 Criminal Proceedings
	  	24
			
	 (iv)
	  	 Investigation
	  	24
			
	 (v)
	  	 Mental Illnesses
	  	25
			
	 (vi)
	  	 Substance Abuse
	  	25
			
	 (vii)
	  	 Professional Ethics.
	  	25
			
	 (viii)
	  	 Application for Licensure.
	  	25
			
	 4.27
	  	 Guaranties.
	  	25
			
	 4.28
	  	 Environment, Health, and Safety.
	  	25
				
	 	  	(a	)	 	 Compliance.
	  	25
				
	 	  	(b	)	 	 Permits and Licenses.
	  	25
				
	 	  	(c	)	 	 Notices.
	  	25
				
	 	  	(d	)	 	 Hazardous Substances.
	  	25
			
	 4.29
	  	 Certain Business Relationships with the Company and its Affiliates.
	  	26
			
	 4.30
	  	 Third-party Payors.
	  	26
			
	 4.31
	  	 Bank Accounts.
	  	26
			
	 4.32
	  	 Tax Status.
	  	26
			
	 4.33
	  	 Binding Obligation.
	  	26
			
	 4.34
	  	 No Corporate Practice or Fee Splitting.
	  	26
			
	 4.35
	  	 Intention.
	  	27

  

 v 

	 	 	 4.36
	  	 Securities Representation.
	  	27
				
	 	 	 	  	(a)    No Registration of PainCare Shares; Investment Intent.	  	27
				
	 	 	 	  	(b)    Resale Restrictions.	  	27
				
	 	 	 	  	(c)    Ability to Bear Economic Risk.	  	27
				
	 	 	 	  	(d)    Accredited Investor.	  	28
				
	 	 	 	  	(e)    Residency.	  	28
				
	 	 	 	  	(f)    No Registration.	  	28
				
	 	 	 4.37
	  	 HIPAA
	  	28
				
	 	 	 4.38
	  	 Improper and Other Payments
	  	28
				
	 	 	 4.39
	  	 Accounts Receivable
	  	28
				
	 	 	 4.40
	  	 Medical Waste
	  	29
				
	 	 	 4.41
	  	 No Untrue or Inaccurate Representation or Warranty
	  	29
			
	 5.
	 	 REPRESENTATIONS AND WARRANTIES OF THE ACQUIRING COMPANIES.
	  	29
				
	 	 	 5.1
	  	 Organization of PainCare and Subsidiary.
	  	29
				
	 	 	 5.2
	  	 Authorization of Transaction.
	  	29
				
	 	 	 5.3
	  	 No Conflict or Violation.
	  	29
				
	 	 	 5.4
	  	 Consents and Approvals.
	  	30
				
	 	 	 5.5
	  	 Disclosure Documents.
	  	30
				
	 	 	 5.6
	  	 Capitalization.
	  	30
				
	 	 	 5.7
	  	 Litigation.
	  	30
				
	 	 	 5.8
	  	 No Undisclosed Liabilities.
	  	31
				
	 	 	 5.9
	  	 No Brokers.
	  	31
				
	 	 	 5.10
	  	 Material Misstatements or Omissions.
	  	31
				
	 	 	 5.11
	  	 No Corporate Practice or Fee Spliting.
	  	31
			
	 6.
	 	 CLOSING; TERMINATION.
	  	31
			
	 7.
	 	 CLOSING DELIVERIES.
	  	31
				
	 	 	 7.1
	  	 Deliveries of the Company and the Shareholder.
	  	32
				
	 	 	 	  	 (a)    Consents and Approvals.
	  	32
				
	 	 	 	  	 (b)    Termination of Agreements.
	  	32

  

 vi 

	 	  	 	  	 (c)
	 	 Company Stock.
	  	32
					
	 	  	 	  	 (d)
	 	 Corporate Authorization.
	  	32
					
	 	  	 	  	 (e)
	 	 Payoffs.
	  	32
					
	 	  	 	  	 (f)
	 	 Good Standing Certificate.
	  	32
					
	 	  	 	  	 (g)
	 	 Secretary’s Certificate.
	  	32
					
	 	  	 	  	 (h)
	 	 Medicare Provider Number.
	  	32
					
	 	  	 	  	 (i)
	 	 Lease.
	  	32
					
	 	  	 	  	 (j)
	 	 Other documents.
	  	32
				
	 	  	 7.2
	  	 Deliveries of PainCare.
	  	32
					
	 	  	 	  	 (a)
	 	 Transaction Consideration.
	  	32
					
	 	  	 	  	 (b)
	 	 Resolutions.
	  	33
					
	 	  	 	  	 (c)
	 	 Lease.
	  	33
					
	 	  	 	  	 (d)
	 	 Other Documents.
	  	33
			
	 8.
	  	 CONDITIONS TO THE OBLIGATIONS OF THE PARTIES
	  	33
				
	 	  	 8.1
	  	 Conditions for the Benefit of PainCare and the Subsidiary.
	  	33
				
	 	  	 8.2
	  	 Conditions for the Benefit of the Shareholder.
	  	33
			
	 9.
	  	 COVENANTS.
	  	33
				
	 	  	 9.1
	  	 Operations Pending Closing.
	  	33
				
	 	  	 9.2
	  	 Deliveries Pending Closings.
	  	33
				
	 	  	 9.3
	  	 Distribution of Sub-Chapter S Income by the Company.
	  	34
				
	 	  	 9.4
	  	 Post-Closing General Covenants.
	  	34
				
	 	  	 9.5
	  	 Tax Returns.
	  	34
				
	 	  	 9.6
	  	 Transitions.
	  	34
				
	 	  	 9.7
	  	 Litigation Support.
	  	35
				
	 	  	 9.8
	  	 Consents.
	  	35
				
	 	  	 9.9
	  	 Operational Covenants.
	  	35
				
	 	  	 9.10
	  	 Capital Adjustments.
	  	36
			
	 10.
	  	 SURVIVAL AND INDEMNIFICATION.
	  	36
				
	 	  	 10.1
	  	 Survival of Representations and Warranties.
	  	36
				
	 	  	 10.2
	  	 Indemnification Provisions for the Benefit of PainCare and Subsidiary.
	  	37

  

 vii 

	 	  	10.3	  	 Indemnification Provisions for the Benefit of the Shareholder.
	  	37
				
	 	  	10.4	  	 Matters Involving Third Parties.
	  	37
					
	 	  	 	  	(a	)	 	 Notification.
	  	37
					
	 	  	 	  	(b	)	 	 Defense by Indemnifying Party.
	  	37
					
	 	  	 	  	(c	)	 	 Satisfactory Defense.
	  	38
					
	 	  	 	  	(d	)	 	 Conditions.
	  	38
				
	 	  	10.5	  	 Right to Set-Off.
	  	38
				
	 	  	10.6	  	 Materiality.
	  	38
				
	 	  	10.7	  	 Limitation.
	  	39
			
	 11.
	  	 LIQUIDATED DAMAGES; CONFIDENTIALITY.
	  	39
				
	 	  	11.1	  	 Liquidated Damages.
	  	39
				
	 	  	11.2	  	 Solicitation.
	  	39
				
	 	  	11.3	  	 No Running of Covenant During Breach.
	  	40
				
	 	  	11.4	  	 Duration & Geographical Limits.
	  	40
				
	 	  	11.5	  	 Reasonable.
	  	40
				
	 	  	11.6	  	 Third-Party Beneficiaries.
	  	40
				
	 	  	11.7	  	 Defenses.
	  	41
				
	 	  	11.8	  	 Blue Pencil Doctrine.
	  	41
				
	 	  	11.9	  	 Confidentiality, Press Releases, and Public Announcements.
	  	41
				
	 	  	11.10	  	 Conduct of Business.
	  	42
				
	 	  	11.11	  	 No Third-Party Beneficiaries.
	  	43
			
	 12.
	  	 MISCELLANEOUS
	  	43
				
	 	  	12.1	  	 Entire Agreement.
	  	43
				
	 	  	12.2	  	 Succession and Assignment.
	  	44
				
	 	  	12.3	  	 Counterparts.
	  	44
				
	 	  	12.4	  	 Headings.
	  	44
				
	 	  	12.5	  	 Notices.
	  	44
				
	 	  	12.6	  	 Governing Law; Jurisdiction; Attorney’s Fees.
	  	45
				
	 	  	12.7	  	 Amendments and Waivers.
	  	45
				
	 	  	12.8	  	 Severability.
	  	45

  

 viii 

	 	  	12.9	  	 Expenses.
	  	45
				
	 	  	12.10	  	 Further Assurances.
	  	45
				
	 	  	12.11	  	 Construction.
	  	45
				
	 	  	12.12	  	 Survival.
	  	46
				
	 	  	12.13	  	 Incorporation of Exhibits and Schedules.
	  	46
				
	 	  	12.14	  	 Submission to Jurisdiction.
	  	46
			
	 13.
	  	 DISPUTE RESOLUTION.
	  	46
				
	 	  	13.1	  	 Dispute Resolution.
	  	46

  

 ix 

 MERGER AGREEMENT AND PLAN OF REORGANIZATION 
  
 THIS MERGER AGREEMENT AND PLAN OF REORGANIZATION (the
“Agreement”) is made and entered into as of this 23rd day of December, 2003 (the “Execution
Date”) by and among PAINCARE HOLDINGS, INC., a Florida corporation (“PainCare”), PAINCARE ACQUISITION COMPANY VI, INC., a Florida corporation (“Subsidiary”, and together with PainCare, the “Acquiring
Companies”), SPINE AND PAIN CENTER, INC., a North Dakota corporation (the “Company”), and MICHAEL P. MARTIRE, M.D., an individual (the “Shareholder”). The Company and the Shareholder are sometimes referred to
herein as the “Sellers.” PainCare, Subsidiary, the Company and the Shareholder are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 
  
 RECITALS 
  
 A. PainCare is in the business of acquiring the non-medical assets of
medical practices and entering into management services agreements with practices entities associated with the acquired practice; 
  
 B. PainCare desires to enter into this Agreement in order for the Subsidiary, which is a wholly-owned subsidiary of PainCare, to acquire the
non-medical assets of the Company; 
  
 C. In connection
with this acquisition, PainCare desires to have Subsidiary enter into a management services agreement with the Shareholder’s professional practice entity, Spine, Orthopedic and Pain Center, P.C. (“New PC”), which management services
agreement is the significant inducement for the Subsidiary to acquire the non-medical assets of the Company; 
  
 D. New PC owns and operates a medical practice (hereinafter sometimes called the “Business”) at 121 West Century Avenue, Bismarck, North
Dakota (hereinafter sometimes called the “Center”) and the Shareholder is a licensed medical provider in the State of North Dakota. The Company owns all of the non-medical assets used in the Business. The Shareholder and owns all of the
issued and outstanding shares of the Company stock and the New PC stock; 
  
 E. All of the Parties hereto desire to enter into this Agreement to effectuate the Merger, as hereinafter defined, of the Company with and into Subsidiary pursuant to the terms and conditions of this Agreement;
and 
  
 F. It is the intention of the Parties for the
Merger contemplated herein to qualify as a tax-free reorganization pursuant to Sections 368(a)(1)(A) and 368(a)(2)(D) of the Code. 
  
 NOW, THEREFORE, in consideration of the premises and the actual promises herein made, and in consideration of the representations, warranties, and
covenants herein contained, the receipt and adequacy of which are hereby conclusively acknowledged, the Parties, intending to become legally bound, hereby agree as follows: 

 TERMS AND CONDITIONS 
  
 1. DEFINITIONS. All capitalized words that are not capitalized for purposes of grammar and which are not defined in the text
of this Agreement are defined terms with their definitions set forth on Exhibit 1. 
  
 2. TRANSACTION. 
  
 2.1
Transaction. Upon the terms and subject to the conditions hereof and in accordance with the provisions of the North Dakota Business Corporation Act (the “North Dakota Act”) and the Florida Business Corporation Act (the
“Florida Act”), the Company shall be merged with and into Subsidiary (the “Merger”) and the separate existence of the Company shall thereupon cease, and Subsidiary, as the surviving corporation (the “Surviving
Corporation”), shall continue to exist under and be governed by the Florida Act (the “Transaction”). 
  
 2.2 Effect of the Merger. At and after the Effective Time, as defined in Section 2.3 below, the effect of the Merger shall, in all respects,
be as provided in the North Dakota Act and the Florida Act. From and after the Effective Time, the Surviving Corporation shall continue to be a Florida corporation and shall take all steps necessary to be properly qualified to do business in the
State of North Dakota. 
  
 2.3 Effective Time; Filing of
Certificates of Merger. The Merger shall be effected by the filing at the time of the Closing or as soon as practicable thereafter, of the Articles of Merger (the “Articles of Merger”), substantially in the form of Exhibit 2.3
attached hereto, with the Secretary of the State of Florida and the Secretary of the State of North Dakota in accordance with the provisions of the Florida Act and the North Dakota Act, respectively. The Merger shall become effective as of 11:59
p.m. on the date of such filing (the “Effective Time”) and the Parties shall take any and all other lawful actions and do any and all other lawful things necessary to cause the Merger to become effective. 
  
 2.4 Articles of Incorporation. As of the Effective Time, the
articles of incorporation of Subsidiary, as in effect immediately prior to the Effective Time, shall be the articles of incorporation of the Surviving Corporation until thereafter amended in accordance with applicable law. 
  
 2.5 Bylaws. As of the Effective Time, the bylaws of Subsidiary, as in
effect immediately prior to the Effective Time, shall be the bylaws of the Surviving Corporation until thereafter amended in accordance with its terms and applicable law. 
  
 2.6 Directors and Officers. As of the Effective Time, the directors and officers of Subsidiary immediately
prior to the Effective Time shall be the directors and officers of the Surviving Corporation. Each director and officer of the Surviving Corporation shall hold office in accordance with the articles of incorporation and bylaws of the Surviving
Corporation. At the Closing, the Company shall cause to be delivered to Subsidiary the written resignations of all of the directors and officers of the Company, which resignations shall be unconditional and effective as of the Closing Date (as
defined in Section 6 below). 

 2.7 Tax Consequences. It is intended by the Parties hereto that the Merger shall constitute
a tax-free reorganization within the meaning of Sections 368(a)(1)(A) and 368(a)(2)(D) of the Code. Pain Care agrees to indemnify and hold harmless the Company, the Surviving Corporation and the Shareholder from any tax liability arising from the
conversion of the Surviving Corporation from cash basis accounting to accrual basis accounting. 
  
 2.8 Additional Actions. If, at any time after the Closing, the Surviving Corporation shall consider or be advised that any further acts are
necessary or desirable: (a) to vest, perfect or confirm, of record or otherwise, in the Surviving Corporation, title to and possession of any property or right of the Company acquired or to be acquired by reason of, or as a result of, the Merger; or
(b) otherwise to carry out the purposes of this Agreement, then the Shareholder shall be deemed to have granted to the Surviving Corporation an irrevocable power of attorney to execute and deliver all such deeds, assignments and assurances in law
and to do all other acts necessary or proper to vest, perfect or confirm title to and possession of such property or rights in the Surviving Corporation and otherwise to carry out the purposes of this Agreement; and the officers and directors of the
Surviving Corporation are fully authorized in the name of the Shareholder and the Company to take any and all such actions. 
  
 2.9 No Dissenters’ Rights. Comprising the sole shareholder of the Company, the Shareholder’s approval and execution of this
Agreement constitutes unanimous approval of the transactions contemplated herein; therefore, neither the Shareholder, nor any other party, is entitled to dissenters’ rights under the laws of the State of North Dakota or the State of Florida.

  
 2.10 Surrender of Certificates. 
  
 (a) Company’s Shares. At the Closing, the Shareholder
shall be required to surrender to Subsidiary the original stock certificate(s) which immediately prior to the Effective Time represented all of the Company Shares (the “Certificates”) (together with all stock powers duly endorsed to
Subsidiary). Until so surrendered, each Certificate which immediately prior to the Effective Time represented the Company Shares (other than Company Shares held in the Company treasury) shall upon and after the Effective Time by virtue of the Merger
be deemed for all purposes to represent and evidence only the right to receive the Merger Consideration, as hereinafter defined, as provided in this Agreement. At the Effective Time, the stock transfer books of the Company shall be closed and no
transfer of the Company Shares shall be made at any time thereafter. 
  
 (b) Dividends. No dividends or other distributions declared or made with respect to the PainCare Shares with a record date after the Closing will be paid to the holder of any unsurrendered Certificate with respect to the
PainCare Shares represented thereby until the holder of record of such Certificate shall surrender such Certificate. Subject to applicable law, following surrender of any such Certificate, there shall be paid to the record holder of the Certificate
representing whole PainCare Shares issued in exchange therefor, without interest, at the time of such surrender, the amount of dividends or other distributions with a record date after the Closing payable with respect to such whole PainCare Shares.

  
 2.11 Medical Assets. Those assets (the
“Medical Assets”) of New PC which require a medical license to own or utilize, such as medical records and any pharmaceutical supplies, shall 

 not become the possession of Subsidiary pursuant to the Merger. All such Medical Assets, which have nominal value, are
owned by New PC as of the Effective Time. Attached hereto as Schedule 2.11 is a list of such Medical Assets together with personal assets of the Shareholder which shall be retained by him. 
  
 2.12 Conversion of Shares. Each share of capital stock of
Subsidiary issued and outstanding immediately prior to the Closing shall continue to represent one (1) validly issued, fully paid and non-assessable share of capital stock of the Surviving Corporation after the Merger. By virtue of the Merger and
without any action on the part of the Shareholder the Company Shares shall be converted into the Merger Consideration. The PainCare Shares to be received by the Shareholder as part of the Merger Consideration shall be subject to restrictions of the
sale, transfer or distribution thereof as set forth in Section 4.36. 
  
 2.13 Shareholder Consent and Release. The Shareholder hereby consents to the Transaction and approves the execution and delivery of this Agreement and the transactions contemplated hereby. Effective on the Effective Time, the
Shareholder hereby releases the Company from any and all claims he may, could or will have, whether arising before the Effective Time, against the Company as a result of the Shareholder having served as a stockholder, director, officer, employee,
agent, or in any other capacity of the Company; provided, however, such release shall not operate to release the Company (or the Surviving Corporation as successor to the Company) from (i) Shareholder’s rights (whether arising under the
Company’s By-Laws or by statute) to indemnification, or (ii) the obligation to make the distributions of pre-Closing Date income as permitted under this Agreement, or (iii) claims, if any, arising from Shareholder serving as a guarantor or
joint-obligor with respect to those certain obligations of the Company as identified in Section 2.13 of the Disclosure Schedule. 
  
 2.14 Piggyback Registration. 
  
 (a) The PainCare Shares are not registered but are governed by Rule 144 promulgated under the 1933 Act. Subject to the conditions and restrictions set
forth in Rule 144, PainCare agrees that the PainCare Shares will be freely transferable upon the expiration of one year and will be freely transferable by the Shareholder following the first anniversary of closing under this agreement. If at anytime
within three (3) year period commencing on the Execution Date, PainCare proposes for any reason to register the PainCare Shares under the Securities Act [other than a registration in connection with an exchange offer (Form S-4) or filed in
connection with an employee stock option or other benefit plan (Form S-8, or any substitute form that may be adopted by the Commission)], PainCare shall promptly give written notice to the Shareholder of its intention to so register the PainCare
Shares and, upon written request by the Shareholder, given within twenty (20) days after delivery of any such notice by PainCare, to include in such registration the PainCare Shares held by the Shareholder (which request shall specify the number of
the PainCare Shares proposed to be included in such registration), PainCare shall attempt to cause all such PainCare Shares to be included in such registration on the same terms and conditions as the securities otherwise being included in such
registration; provided however, that if the managing underwriters advise PainCare that the inclusion of the PainCare Shares proposed to be included in such registration would interfere with the successful marketing (including pricing) of the
PainCare Shares proposed to be registered by PainCare, then if such registration is in part an underwritten primary or secondary registration on behalf of PainCare, PainCare shall 

 include in such registration the PainCare Shares requested to be included in such registration, pro rata from among the
holders of any and all PainCare shares to be registered pursuant to such registration according to the number of shares proposed by each holder to be included. In the event PainCare determines not to pursue, or to withdraw, a registration as to
which it has given notice pursuant to this section, the Shareholder shall have no further rights hereunder with respect to such proposed registration, and the Shareholder shall continue to have the rights set forth above with respect to any other
registrations to be proposed or undertaken thereafter. Notwithstanding any other provision of this Section to the contrary, PainCare shall not be required to include any of the PainCare Shares in a registration statement relating to an underwritten
offering of PainCare’s securities unless the Shareholder accepts the terms of the underwriting as agreed upon between PainCare and the underwriters selected by it, including, without limitation, any Underwriter’s Cutback and/or Lockup, and
the Shareholder agrees to promptly execute and/or deliver such documents in connection with such registration as PainCare or the managing underwriter may reasonably request. 
  
 (b) The Shareholder may exercise his rights under Section 2.14(a) above on an unlimited number of occasions. PainCare shall
pay all Registration Expenses (as defined below) of any registration effected under this Section, except that in the event of withdrawal by the Shareholder, the Shareholder shall pay (or reimburse PainCare for) the amount of registration, filing or
listing fees relating to his PainCare Shares included in the registration and shall pay the fees of PainCare’s counsel associated with such withdrawal, unless such withdrawal is due to the Shareholder obtaining material adverse information that
was not known by him at the time he requested inclusion of his PainCare Shares in the registration. 
  
 (c) The Shareholder may not participate in any registration under this Section which is underwritten unless he agrees to sell such PainCare Shares on the
basis provided in any underwriting agreement (with terms not inconsistent herewith, or rights less than those provided to any other common shareholder of PainCare with similar piggy-back rights and customary in underwriting agreements for secondary
distributions) approved by PainCare, provided that the Shareholder shall not be required to make any representations or warranties to PainCare or the underwriters (other than representations and warranties regarding such Shareholder and such
Shareholder’s intended method of distribution). 
  
 2.15
Shareholder’s Obligation to Furnish Information. PainCare may require Shareholder to furnish PainCare such information regarding the distribution of such securities as PainCare may from time to time reasonably request. If the
failure by the Shareholder to furnish such information as expeditiously as possible would prevent (i) the registration statement relating to such registration from being declared effective by the Securities Exchange Commission, or (ii) members of
the National Association of Securities Dealers, Inc. from participating in the distribution of the PainCare Shares proposed to be registered, PainCare may exclude the Shareholder’s PainCare Shares from such registration. 
  
 2.16 Suspension of Sales Pending Amendment to Prospectus.

  
 (a) The Shareholder agrees that, upon receipt of any notice
from PainCare of the happening of any event of that requires PainCare not to proceed with the registration, or if PainCare has decided not to proceed with the registration for any reason, the Shareholder shall 

 forego the disposition of any PainCare Shares covered by the registration statement or prospectus until he is advised in
writing by PainCare that the use of the applicable prospectus may be resumed and, if so directed by PainCare, the Shareholder shall deliver to PainCare (at PainCare’s expense, except as hereinafter provided) all copies, other than permanent
file copies, then in Shareholder’s possession of any prospectus covering such PainCare Shares. 
  
 (b) The Shareholder agrees that he shall, as expeditiously as possible, notify PainCare at any time of the happening of any event for which he has
information or knowledge which requires changes to be made in a registration statement or any related prospectus so that such registration statement or prospectus shall not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein not misleading as a result of any information previously provided or omitted by the Shareholder for inclusion in such prospectus or such registration statement
and, at the request of PainCare, as expeditiously as possible prepare and furnish to it such information as may be necessary so that, after incorporation into a supplement or amendment of such prospectus as thereafter delivered to the purchasers of
such PainCare Shares, the information provided by such Shareholder shall not include an untrue statement of a material fact or a misstatement of a material fact required to be stated therein or necessary to make the statements made therein, in light
of the circumstances under which they are made, not misleading. 
  
 2.17 Registration Expenses. 
  
 (a) All
expenses incident to PainCare’s performance of or compliance with its obligations under this Section 2, including without limitation all (i) registration and filing fees, (ii) fees and expenses of compliance with securities laws, (iii) printing
expenses, (iv) messenger and delivery expenses, (v) internal expenses, (vi) reasonable fees and disbursements of its counsel and its independent certified public accountants (including “comfort” letters), (vii) securities act liability
insurance, (viii) reasonable fees and expenses of any special experts retained by PainCare in connection with the registration hereunder, and (ix) reasonable fees and expenses of other persons retained by PainCare (all such expenses being referred
to herein as “Registration Expenses”) shall be borne by PainCare. 
  
 (b) Notwithstanding the foregoing, the following costs and expenses shall be excluded from the term “Registration Expenses”: (i) all underwriting discounts and commissions to the extent applicable to all
holders of PainCare capital stock subject to the registration, (ii) all applicable transfer taxes to the extent applicable to all holders of PainCare capital stock subject to the registration, (iii) the fees and disbursements of any counsel retained
by the Shareholder, and (iv) except as provided in Section 2.17(a), all other costs, fees, and expenses incurred by the Shareholder in connection with the exercise of his registration rights hereunder. 
  
 3. TRANSACTION CONSIDERATION. 
  
 3.1 Merger Consideration. The aggregate merger consideration
(the “Merger Consideration”) shall consist of (i) the Closing Date Consideration (the “Closing Date Consideration”) as hereafter defined, and (ii) the Earnout Payment as determined under Section 3.4 below. Subject to adjustment
as provided in Section 3.3 below, the Closing Date Consideration that PainCare shall transfer to the Shareholder shall equal One Million Two 

 Hundred Fifty Thousand and 00/100 Dollars ($1,250,000), comprised of: (i) Six Hundred Twenty Five Thousand and 00/100
Dollars ($625,000) (the “Cash Due At Closing”) to be delivered via wire transfer on the Closing Date to a bank account designated by the Shareholder, plus (ii) Two Hundred Seventy Seven Thousand Seven Hundred Seventy Eight (277,778)
PainCare Shares, valued at Two Dollars and Twenty Five Cents ($2.25) per share and having an aggregate value of Six Hundred Twenty Five Thousand and 00/100 Dollars ($625,000). At least five (5) days prior to the Closing Date, the Shareholder shall
notify PainCare in writing of the bank account to which the Cash Due At Closing shall be wired. 
  
 3.2 Intentionally Omitted. 
  
 3.3 Closing Date Adjustments. The Closing Date Consideration shall be subject to adjustment as follows: 
  
 (a) Transaction Related Adjustments. The Cash Due At Closing
shall be reduced by the amount of any cash payments made by the Company or the Acquiring Companies (i) in satisfaction of the joint obligation of the Company and the Shareholder to pay the broker named in Section 4.5 below, (ii) other expenses paid
on behalf of the Shareholder (rather than the Company) expect as otherwise specifically allowed pursuant to this Agreement, and (iii) the cash portion of any bonus or incentive compensation directed by Shareholder to be paid to employees of the
Company at Closing. Similarly, to the extent that any portion of the obligation of the Company and the Shareholder to the broker under Section 4.5 below is to be satisfied in shares of the PainCare Shares, the number of the PainCare Shares
comprising a portion of the Closing Date Consideration shall be reduced by the aggregate number of shares so issued. Shareholder and the Company acknowledge that the obligation of PainCare to issue shares to others in accordance with the previous
sentence is conditioned upon the availability of exemption(s) from the registration requirements under the Securities Act and any applicable state securities law for such transaction(s) and the agreement(s) of the recipients thereof to restrictions
on the transfer, sale or distribution thereof. 
  
 (b)
Financial Statements. The Company has prepared financial statements consisting of (i) a balance sheet, statement of operations in accordance with GAAP as of and for the year ended December 31, 2002 (the “GAAP Financial
Statements”); and (ii) a balance sheet and a statement of operations as of and for the quarters ended June 30, 2002 and 2003; (the “Interim Financial Statements”) all of which are included in Section 3.3(b) of the Disclosure Schedule.
The GAAP Financial Statements have been certified by an independent auditor and have been prepared using accounting principles consistent with the accounting principles utilized by PainCare. The Interim Financial Statements have been prepared in
accordance with the cash method of accounting. The GAAP Financial Statements and the Interim Financial Statements (collectively, the “Financial Statements”) present fairly the financial condition of the Company as of such dates and the
results of the operations of the Company for such periods, are correct and complete, and are consistent with the books and records of the Company (which books and records are correct and complete). 
  
 (c) Closing Date Balance Sheet. Within forty-five (45) days
after the Closing Date, PainCare or its Affiliate will prepare and deliver to the Shareholder a balance sheet of the Company as of the close of business on the Closing Date prepared in accordance with 

 
GAAP (the “Closing Date Balance Sheet”). Within twenty (20) days after PainCare’s delivery of the Closing Date Balance Sheet to the
Shareholder, the Shareholder shall, in a written notice to PainCare, either accept or describe in reasonable detail any proposed adjustments to the Closing Date Balance Sheet and the reasons therefore, and shall include pertinent calculations. If
the Shareholder fails to deliver notice of acceptance or objection to the Closing Date Balance Sheet within such twenty (20) day period, the Shareholder shall be deemed to have accepted the Closing Date Balance Sheet. Except in the case of a dispute
with respect to the Closing Date Balance Sheet, within twenty (20) days after delivery of the Closing Date Balance Sheet (the “Adjustment Payment Date”), the Shareholder shall pay the Other Net Equity Adjustment (as defined below) to
PainCare. In the event that PainCare and the Shareholder are not able to agree on the Closing Date Balance Sheet within thirty (30) days from and after the receipt by PainCare of any objections raised by the Shareholder, then either Party shall each
have the right to require that such disputed determinations be submitted to an independent certified public accountant or accounting firm mutually acceptable to the Parties, for computation or verification in accordance with the provisions of this
Agreement, and the Net Equity Adjustment shall be paid by the Shareholder to PainCare within five (5) days after receipt of the accountant’s computation or verification. Such accounting firm’s fees and expenses for such disputed
determination shall be borne by the Party whose determination has been modified by such accounting firm’s report or by all Parties in proportion to the relative amount each Party’s determination has been modified. Any payments due under
this Section 3.3 shall bear interest at eight percent (8%) per annum from the Adjustment Payment Date. 
  
 If the final Closing Date Balance Sheet reflects Cash of the Company that is less than Twenty Thousand Dollars ($20,000) (the “Required Cash”),
then the Merger Consideration shall be reduced and the Shareholder shall be required to immediately return to PainCare dollar for dollar an Amount equal to the Required Cash less Cash reflected on the Closing Date Balance Sheet (the “Cash
Deficiency”). The Cash Deficiency shall be paid in cash. 
  
 3.4 Earnout Payment. 
  
 (a)
General. Subject to the condition that the Surviving Corporation achieves Formula Period Profits (as defined in Subsection (f) below) of at least Five Hundred Thousand and 00/100 Dollars ($500,000) (the “Earnings Threshold”)
in each of the three (3) successive twelve (12) month calendar periods beginning on January 1, 2004 (each such twelve (12) month calendar period shall be referred to herein as a “Formula Period”), then PainCare shall pay to the Shareholder
a total amount of additional consideration of One Million Two Hundred Fifty Thousand and 00/100 Dollars ($1,250,000) for all of the Formula Periods, payable in three equal annual installments of Four Hundred Sixteen Thousand Six Hundred Sixty Six
and 67/100 Dollars ($416,666.67) (the “Intended Installment Payment”) in the form of consideration and subject to adjustment as provided in Section 3.4(d) below. 
  
 (b) Installment Payment Discount. Notwithstanding Section 3.4(a) above, if the Surviving Corporation fails to
achieve the Earnings Threshold in a Formula Period, the amount of the Intended Installment Payment for such Formula Period shall be recalculated to equal the product of the Intended Installment Payment, multiplied by the Installment Payment Discount
(as defined below) (the “Adjusted Installment Payment”). The “Installment Payment Discount” shall equal (i) the Formula Period Profits (as defined in Subsection (f) below) for such Formula Period divided by the Earnings
Threshold; multiplied by (ii) ninety percent (90%). 

 (c) Installment Payment Premium. Notwithstanding Section 3.4(b), if (i) the Shareholder
receives the Adjusted Installment Payment from PainCare in a Formula Period rather than the Intended Installment Payment as a result of the Formula Period Profits equaling less than the Earnings Threshold for such Formula Period, and (ii) the
Subsidiary’s Formula Period Profits exceed the Earnings Threshold in the Formula Period immediately subsequent to the Formula Period for which the Installment Payment Discount corresponded, then PainCare shall pay to the Shareholder the
Installment Payment Premium (as defined below). The “Installment Payment Premium” shall equal the product of (A) the Formula Period Profits for the Formula Period in which the Installment Payment Premium is calculated less the Earnings
Threshold, multiplied by (B) Seventy-five percent (75%). The Installment Payment Premium shall be paid to the Shareholder in the same percentages, form and time as the Installment Payments (as defined in Subsection (d) below) are due for the Formula
Period for which the Installment Payment Premium is calculated. 
  
 (d) Manner of Payment. Within sixty (60) days after the end of each Formula Period, PainCare or its Affiliate shall prepare and deliver to the Shareholder a financial statement presenting the Formula Period Profits for the
Surviving Corporation for the applicable Formula Period (the “Formula Period Profits Statement”). Twenty (20) days after delivery of the Formula Period Profits Statement, the Shareholder shall in a written notice to PainCare either accept
or describe in reasonable detail any proposed adjustments to the Formula Period Profits Statement and the reasons therefore, and shall include pertinent calculations. If the Shareholder fails to deliver notice of acceptance or objection to the
Formula Period Profits Statement within such Twenty (20) day period, the Shareholder shall be deemed to have accepted the Formula Period Profits Statement. If the Shareholder accepts or fails to object to the Formula Period Profits Statement within
the Twenty (20) day period set forth above, then within ninety (90) days after the end of the Formula Period, PainCare shall pay to the Shareholder the Intended Installment Payment or the Adjusted Installment Payment (each an “Installment
Payment”, and collectively, the “Installment Payments”) along with any Installment Payment Premium owed in accordance with Subsection (c) above as follows: (i) fifty percent (50%) of the Installment Payment shall be made in cash via
wire transfer to a bank account designated by the Shareholder at least five (5) days prior to the end of the Formula Period; and (ii) fifty percent (50%) of the Installment Payment shall be made in the PainCare Shares priced at Fair Market Value (as
defined below) per one share of PainCare common stock for all Formula Periods. In the event PainCare and the Shareholder are not able to agree on the Formula Period Profits Statement within thirty (30) days from and after the receipt by PainCare of
any objections raised by the Shareholder, PainCare and the Shareholder shall each have the right to require that such disputed determinations be submitted to an independent certified public accountant or accounting firm mutually acceptable to the
parties, for computation or verification in accordance with the provisions of this Agreement, and the Installment Payment shall be paid by PainCare to the Shareholder within fifteen (15) days after receipt of the accountant’s computation or
verification. Notwithstanding, if any Party objects to the findings of the independent certified public accountant or accounting firm it shall provide the other Parties of written notice of its objection within ten (10) days after receipt of the
accountant’s computation and in such event if the Parties are still unable to reach an agreement the matter shall be resolved in accordance with Section 13 

 
of this Agreement. The Failure by any Party to deliver written notice of any objection to the other Parties within ten (10) days after receipt of the
accountant’s computation shall automatically result in the computation of such accountant becoming final and binding upon the Parties and there shall be no right of appeal from such decision. 
  
 (e) Earnout Cap. Notwithstanding anything to the contrary in
this Section 3, in no event whatsoever shall the aggregate amount of the Installment Payments paid to the Shareholder from PainCare in cash, in PainCare Shares or any other form of consideration exceed One Million Two Hundred Fifty Thousand and
00/100 Dollars ($1,250,000). 
  
 (f) Definitions for
Purposes of Section 3.4. For purposes of Section 3.4 of this Agreement: 
  
 (i) “Fair Market Value” shall mean the value of the PainCare Shares determined as follows: 
  
 (1) if the principal market for the PainCare Shares is a national securities exchange, then the “Fair Market Value” of the PainCare Shares
shall equal the sixty (60) day trailing average of the closing ask prices of the PainCare Shares as reported by such exchange or on a composite tape reflecting transactions on such exchange; or 
  
 (2) if the principal market for the PainCare Shares is not a national
securities exchange, but the price of the PainCare Shares is quoted on the National Association of Securities Dealers Automated Quotation System (“NASDAQ”) Stock Market, and (A) actual closing price information is available with respect to
the PainCare Shares, then the “Fair Market Value of the PainCare Shares shall equal the sixty (60) day trailing average of the closing ask prices of such stock on the NASDAQ Stock Market; or (B) actual closing price information is not available
with respect to the PainCare Shares, then the “Fair Market Value” of the PainCare Shares shall equal the sixty (60) day trailing average of the bid prices per share of such stock on the NASDAQ Stock Market; or 
  
 (3) if the principal market for the PainCare Shares is neither a national
securities exchange and such stock is not quoted on NASDAQ, then the “Fair Market Value” of the PainCare Shares shall equal the sixty (60) day trailing average of the closing ask prices of the PainCare Shares as reported by the OTC
Bulletin Board Service or by National Quotation Bureau, Incorporated, or a comparable service selected by PainCare; or 
  
 (4) if subsections (f)(i)(1)-(3) above are inapplicable or if no trades have been made or no quotes are available for such day with respect to the
PainCare Shares, then the “Fair Market Value” of the PainCare Shares shall be determined by an independent third party appraiser selected by PainCare. Within ten (10) days after the effective date of the appraiser’s appointment, the
appraiser shall deliver an appraisal of the Fair Market Value of the PainCare Shares, which shall be binding and conclusive on the Parties. The cost of any appraisal hereunder shall be shared equally by the Parties, and each Party shall be
responsible and financially liable for its or his own attorneys’ fees and 
  
 (5) with the understanding that notwithstanding the Fair Market Value ascribed to the PainCare Shares pursuant to subsections 3.4(f)(1), (2), (3) or (4) above in no event shall the Fair Market Value of the PainCare
Shares ever be less than One and 00/00 Dollars ($1.00) per share. 

 (ii) “Formula Period Profits” shall mean the Surviving Corporation’s earnings before
deductions for interest, taxes, depreciation and amortization (“EBITDA”) as calculated utilizing GAAP by PainCare’s independent certified public accountants for the applicable Formula Period where possible, and as calculated by
PainCare for quarterly and less than quarterly data for such Formula Period. Notwithstanding the foregoing, the calculation of the Formula Period Profits shall not include any costs or expenses related to: (i) the corporate overhead of PainCare or
other administrative or similar charges that PainCare might impose upon the Subsidiary, except those charges for services provided directly to and for the benefit of the Subsidiary; (ii) any non-recurring charges, losses, profits, gains, or non-cash
adjustments not related to the ongoing operations of the Subsidiary’s business, including but not limited to discontinued operations, extraordinary items, acquisition costs and goodwill charges incurred in connection with the transactions
contemplated hereby (excluding the write-off of any goodwill with respect to the Surviving Corporation in accordance with FASA 142), or unusual or infrequent items as such terms are defined pursuant to generally accepted accounting principles, (iii)
any charge related to grants or exercises of options pursuant to the Employment Agreement which was be entered into by and between the Shareholder and the New PC on even date herewith. 
  
 (g) Adjustments to Installment Payments. The amount of the cash portion of any Installment Payment due
Shareholder hereunder shall be reduced by the amount of any cash payments made by the Acquiring Companies in satisfaction of the joint obligation of the Company and the Shareholder to pay the broker named in Section 4.5 below. Similarly, to the
extent that any portion of the obligation of the Company and the Shareholder to the broker under Section 4.5 below is to be satisfied in shares of PainCare Common Stock, the number of shares of PainCare Common Stock comprising a portion of any
Installment Payment shall be reduced by the aggregate number of shares so issued. Shareholder and the Company acknowledge that the obligation of PainCare to issue shares to others in accordance with the previous sentence is conditioned upon the
availability of exemption(s) from the registration requirements under the Securities Act and any applicable state securities law for such transaction(s) and the agreement(s) of the recipients thereof to restrictions on the transfer, sale or
distribution thereof. 
  
 3.5 Intentionally Omitted.

  
 4. REPRESENTATIONS AND WARRANTIES OF THE SHAREHOLDER. The
Shareholder represents and warrants to the Acquiring Companies that the statements contained in this Section 4 are correct and complete as of the date of this Agreement, except as set forth in the disclosure schedule accompanying this Agreement (the
“Disclosure Schedule”). The Disclosure Schedule will be arranged in paragraphs corresponding to the numbered paragraphs contained in this Section 4 to the Agreement. 
  
 4.1 Organization, Qualification, and Corporate Power. The Company is a corporation duly organized, validly
existing, and in good standing under the laws of the State of North Dakota. The Company has full power and authority and all licenses, permits and authorizations necessary to carry on the businesses in which it is currently engaged and to own

 and use the properties owned and used by it. Section 4.1 of the Disclosure Schedule lists all of the officers and members
of the Board of Directors of the Company, as of the date immediately preceding the Closing Date. The Company has made available to the Acquiring Companies correct and complete copies of the minute book, articles of incorporation and bylaws of the
Company, as amended to date. Copies of the minute book (containing the records of meetings of the stockholders, the board of directors and any committees of the board of directors), the stock certificate books and stock record books of the Company
are correct and complete in all material respects and will have been delivered to PainCare prior to or at the Closing. The Company is not in default under or in violation of any provision of its articles of incorporation or bylaws. 
  
 4.2 Capitalization. The entire authorized capital stock of the
Company consists of one thousand (1,000) shares of common stock, $1.00 par value, all of which are issued and outstanding. All of the issued and outstanding Company Shares have been duly authorized, are validly issued, fully paid, and nonassessable
and are held of record by the Shareholder as set forth in Section 4.2 of the Disclosure Schedule. The Shareholder has good title to the Company Shares free and clear of any and all liens, claims, security interests or other encumbrances of any
Person. There are no outstanding or authorized options, warrants, purchase rights, subscription rights, redemption rights, conversion rights, exchange rights, or other contracts or commitments that could require the Company to issue, sell, or
otherwise cause to become outstanding any of its capital stock. There are no outstanding or authorized stock appreciation, phantom stock, profit participation, or similar rights with respect to the Company. There are no stockholders’
agreements, voting trusts, proxies, or other agreements or understandings with respect to the voting of the capital stock of the Company. 
  
 4.3 Authorization. The Company has full power and authority (including full corporate power and authority) and the Shareholder has all
necessary authority to execute and deliver this Agreement and to perform its obligations hereunder. The execution, delivery and performance of this Agreement by the Company has been duly authorized and approved by its board of directors and no other
corporate proceedings on the part of the Company are necessary to authorize this Agreement and the transactions contemplated hereby. The Company has given the Shareholder any and all notice required to be given to the Shareholder under applicable
law. This Agreement constitutes the valid and legally binding obligation of the Company and the Shareholder, enforceable in accordance with its terms and conditions. 
  
 4.4 Noncontravention. Except as set forth in Section 4.4 of the Disclosure Schedule, neither the execution and
the delivery of this Agreement by the Company or the Shareholder, nor the consummation of the transactions contemplated hereby will, to the Shareholder’s Knowledge: (a) violate any constitution, statute, regulation, rule, injunction, judgment,
order, decree, ruling, or other restriction of any government, governmental agency or any other third party whatsoever, or court to which the Company or the Shareholder are subject, or any provision of the articles of incorporation or bylaws of the
Company; or (b) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify, or cancel, or require any notice under any agreement, contract, lease,
license, instrument or other arrangement to which the Company or the Shareholder are a party or by which either the Company or the Shareholder is bound or to which any of the Company’s assets are subject (or result in the imposition of any
Security Interest upon any of its assets). Except as set forth in Section 4.4 of the Disclosure Schedule, to the Shareholder’s 

 Knowledge the Shareholder and the Company need not give any notice to, make any filing with, or obtain any authorization,
consent, or approval of any government or governmental agency or any other third party whatsoever in order for the Parties to consummate the transactions contemplated by this Agreement. The Parties agree that Section 4.4 of the Disclosure Schedule
shall be divided into two (2) sections, consisting of: (i) Section 4.4(a) which shall list all such authorizations, consents and approvals which must be obtained prior to the Closing, as a condition to Closing; and (ii) Section 4.4(b) which shall
list all such authorizations, consents and approvals which will not be obtained prior to Closing which shall be obtained within a reasonable period of time after Closing. 
  
 4.5 Broker’s Fees. The Company and the Shareholder have entered into a Broker’s Agreement dated
December 1, 2001 with Martin Acquisitions Group, LLC (“Broker”) for which the Shareholder agrees to pay any and all Liabilities or obligations to pay any fees, expenses, or commissions to Broker and any other consultant, broker, finder, or
agent retained by the Company or the Shareholder with respect to the transactions contemplated by this Agreement. 
  
 4.6 Title to Assets. Section 4.6 of the Disclosure Schedule contains a complete, true and correct list of all of the assets of the Company.
Except as to assets disposed of in the ordinary course of business subsequent to the date hereof and as otherwise contemplated by this Agreement, the Company has good and marketable title to, or a valid leasehold interest in, the properties and
assets used by it, located on its premises, or shown on the Effective Date Balance Sheet or acquired after the date thereof, free and clear of all Security Interests. Except for the Medical Assets which are to be transferred to New PC and personal
assets retained by the Shareholder, the assets set forth in Section 4.6, in conjunction with any assets which the Company leases, constitute all of the assets used by the Company in connection with its business as presently conducted and all assets
necessary or appropriate for the continued operation of the Company’s business. 
  
 4.7 No Subsidiaries. The Company has no Subsidiaries and does not control, directly or indirectly, or have any direct or indirect equity participation in any corporation, partnership, limited liability
company, trust or other business association. 
  
 4.8
Financial Statements. Attached as Section 3.3(b) of the Disclosure Schedule are true and complete copies of the GAAP Financial Statements and the Interim Financial Statements. Except as provided in the Interim Financial Statements, or
as fully disclosed in Section 4.8 of the Disclosure Schedule, the Company does not have any Liabilities or obligations (whether accrued, absolute, contingent, whether due or to become due or otherwise) which might be or become a charge against the
Company since the date of the Interim Financial Statements. The Shareholder acknowledges and agrees that PainCare and Subsidiary relied upon the financial information set forth in the Financial Statements in order to determine the Transaction
Consideration. 
  
 4.9 Events Subsequent to Most Recent Year
End. Since December 31, 2002 (the “Most Recent Year End”), there has not been any material adverse change in the business, financial condition, operations, results of operations, or future prospects of the Company. Without limiting
the generality of the foregoing, since the Most Recent Year End: 
  
 (a) Sale or Lease of Assets. The Company has not sold, leased, transferred, or assigned any of its assets, tangible or intangible, other than for fair market value in the ordinary course of its business; 

 (b) Contracts. The Company has not entered into any agreement, contract, lease, or license
(or series of related agreements, contracts, leases, and licenses) outside the ordinary course of business; 
  
 (c) Change in Contracts. To the Shareholder’s Knowledge, no third party (or the Company) has accelerated, terminated, modified, or
canceled any agreement, contract, lease, or license (or series of related agreements, contracts, leases, and licenses) to which the Company is a party or by which it is bound and neither the Shareholder nor the Company has any intent to do any of
the foregoing or has received a verbal or written indication of any third party’s intent to do any of the foregoing; 
  
 (d) Security Interests. To the Shareholder’s Knowledge, the Company has not had imposed any Security Interest upon any of its assets,
tangible or intangible; 
  
 (e) Investments. The
Company has not made any capital investment in, any loan to, or any acquisition of the securities or assets of, any other Person (or series of related capital investments, loans, and acquisitions); 
  
 (f) Debts. The Company has not issued any note, bond, or other
debt security or created, incurred, assumed, or guaranteed any indebtedness for borrowed money or capitalized lease obligation; 
  
 (g) Liabilities Unaffected. The Company has not delayed or postponed the payment of accounts payable and other Liabilities or accelerated
the collection of accounts, notes or other receivables, except in the ordinary course of business consistent with past practice; 
  
 (h) Claims Unaffected. The Company has not canceled, compromised, waived, or released any right or claim (or series of related rights and
claims) outside the ordinary course of its business; 
  
 (i)
Articles and Bylaws. There has been no change made or authorized in the articles of incorporation or bylaws of the Company; 
  
 (j) Changes in Equity. The Company has not issued, sold, or otherwise disposed of any of its capital stock, or granted any options,
warrants, or other rights to purchase or obtain (including upon conversion, exchange, or exercise) any of its capital stock; 
  
 (k) Distribution. Except for distributions of subchapter S income as permitted by Section 9.3 below, the Company has not declared, set
aside, or paid any dividend or made any distribution with respect to its capital stock (whether in cash or in kind) or redeemed, purchased, or otherwise acquired any of its capital stock; 
  
 (l) Property Damage. The Company has not experienced any material damage, destruction, or loss (whether or not
covered by insurance) to its property or assets; 

 (m) Transactions with Affiliates. The Company has not made any loan to, or entered into any
other transaction with, any of its directors, officers and employees; 
  
 (n) Collective Bargaining Agreements. The Company has not entered into any collective bargaining agreement, written or oral, or modified the terms of any existing such contract or agreement; 
  
 (o) Compensation Changes. The Company has not granted any
increase in the base compensation of any of its directors, officers, and employees; 
  
 (p) Employee Benefit Plans. Except as set forth in Schedule 4.9(p), the Company has not adopted, amended, modified, or terminated any bonus, profit-sharing, incentive, severance, or other plan, contract,
or commitment for the benefit of any of its directors, officers, and employees (or taken any such action with respect to any other Employee Benefit Plan); 
  
 (q) Officers; Directors; Employees. The Company has not made any change in the employment terms for any of its directors, officers and
employees, other than to terminate such agreements as required herein; 
  
 (r) Charitable or Capital Contributions. Except as set forth in Schedule 4.9(r), the Company has not made or pledged to make any charitable or other capital contribution; 
  
 (s) Ordinary Course of Business. There has not been any other
occurrence, event, incident, action, failure to act, or transaction outside the ordinary course of business involving the Company; 
  
 (t) Accounting Practices. Saving the changes associated with the change to GAAP with respect to the GAAP Financial Statements, there has not
been any change in any method of accounting or accounting principle, estimate or practice of the Company; 
  
 (u) Accounts Receivable. The Company has not accelerated the collection of any Accounts Receivable or any other amounts owed to it; and

  
 (v) In General. Neither the Company nor the
Shareholder has committed to do any of the foregoing. 
  
 4.10
Undisclosed Liabilities. The Company has no Liability and to the Shareholder’s Knowledge there is no basis for any present or future action, suit, proceeding, hearing, investigation, complaint, claim, or demand against it giving
rise to any Liability, except for: (a) Liabilities disclosed in the Disclosures Schedule; (b) contractual obligations incurred in the ordinary course of business; and (d) Liabilities which have arisen after the Interim Balance Sheet in the ordinary
course of business (none of which results from, arises out of, relates to, is in the nature of, or was caused by any breach of contract, breach of warranty, tort, infringement, or violation of law). As of the Closing, other than the current trade
accounts payable, leasehold obligations and accrued payroll and benefit obligations, the Company shall not have any unpaid liabilities, other than those listed in the Section 4.10 Disclosure Schedule, including, but not 

 limited to, any bank debt, capital leases or any general or professional liability claims, or be obliged in any other way
to provide funds in respect of, or to guarantee or assume, any debt, obligation or dividend of any person, except endorsements in the ordinary course of business in connection with the deposit, in banks or other financial institutions, of items for
collection. 
  
 4.11 Tax Matters. 
  
 (a) Tax Returns. The Company has filed all Tax Returns it was
required to file. All such Tax Returns were correct and complete in all respects and were filed on a timely basis. All Taxes owed by the Company (whether or not shown on any Tax Return) have been paid. The Company currently is not the beneficiary of
any extension of time within which to file any Tax Return. No claim is currently pending by an authority in a jurisdiction where the Company is or may be subject to taxation by that jurisdiction. There are no Security Interests on any of the assets
of the Company that arose in connection with any failure (or alleged failure) to pay any Tax. 
  
 (b) Withholding. The Company has withheld, and remitted when due, all Taxes required to have been withheld or paid in connection with amounts paid or owing to any employee, independent contractor,
creditor, stockholder, or other third party. 
  
 (c) No
Disputes of Claims. No Shareholder or director or officer (or employee responsible for Tax matters) of the Company expects any authority to assess any additional Taxes for any period for which Tax Returns have been filed. There is no dispute
or claim concerning any Tax Liability of the Company either: (a) claimed or raised by any authority in writing; or (b) as to which any of the Shareholder, directors and officers (and employees responsible for Tax matters) of the Company has
Knowledge based upon personal contact with any agent of such authority. Section 4.11 of the Disclosure Schedule lists all federal, state, local, and foreign income Tax Returns filed with respect to the Company for taxable periods ended on or after
December 31, 2002, indicates those Tax Returns that have been audited, and indicates those Tax Returns that currently are the subject of audit. The Shareholder has made available to PainCare correct and complete copies of all federal income Tax
Returns, examination reports, and statements of deficiencies assessed against or agreed to by any of the Company and its Affiliates since December 31, 2002. 
  
 (d) No Waivers. The Company has not waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to
a Tax assessment or deficiency. 
  
 (e) No Special
Circumstances. The Company has not made any payments, is not obligated to make any payments, nor is a party to any agreement that under certain circumstances could obligate it to make any payments that will not be deductible under Code
Section 280G. The Company has not been a United States real property holding corporation within the meaning of Code Section 897(c)(2) during the applicable period specified in Code Section 897(c)(1)(A)(ii). The Company has disclosed on its federal
income Tax Returns all positions taken therein that could give rise to a substantial understatement of federal income Tax within the meaning of Code Section 6662. 

 (f) Subchapter “S”. The Company has elected, by the unanimous consent of its
shareholders and in compliance with all applicable legal requirements, to be taxed under Subchapter “S” of the Code and corresponding provisions under any applicable state and local laws, and such elections are currently in full force and
effect for the Company. No action has been taken by the Company or the Shareholder that may result in the revocation of any such elections. The Company has no “Subchapter C earnings and profits,” as defined in Code Section 1362(d). The
Company has no “net unrealized built-in gain,” as such term is defined in Code Sections 1374(d)(1) and 1374(d)(8). The Company has no Liability, absolute or contingent, for the payment of any income Taxes under the Code or under Subchapter
“S” of the Code. 
  
 (g) Audits of Tax
Returns. No Tax Return of the Company is currently under audit or examination by any taxing authority, and the Company has not received a written notice stating the intention of any taxing authority to conduct such an audit or examination.
Each deficiency resulting from any audit or examination relating to Taxes by any taxing authority has been paid, except for deficiencies being contested in good faith. The revenue agents’ reports related to any prior audits and examinations are
attached as part of Section 4.11 of the Disclosure Schedule. 
  
 (h) Period of Assessment. There is no agreement or other document extending, or having the effect of extending, the period of assessment or collection of any Taxes. 
  
 (i) Tax Agreements. The Company is not a party to or bound by any tax sharing agreement, tax indemnity
obligation or similar agreement with respect to Taxes, including any advance pricing agreement, closing agreement or other agreement relating to Taxes with any taxing authority. 
  
 (j) Inclusions in Taxable Periods. The Company will be required to include in a taxable period ending after
the Closing Date taxable income attributable to income that recorded in a prior taxable period but was not recognized in any prior taxable period occurring before the Closing Date. As of the Closing Date and except as set forth in Schedule 9.5
below, the Shareholder will place funds in a separate bank account in the name of the Company in an amount sufficient to pay all such liabilities, if any, and such funds shall be used to pay such liabilities as they become due. 
  
 (k) Consents. The Company has not filed a consent pursuant to
or agreed to the application of Code Section 341(f). 
  
 (l)
Personal Holding Company. The Company has not, during the five (5) year period ending on the Closing Date, been a personal holding company within the meaning of Code Section 541. 
  
 (m) Consolidated Tax Returns. The Company has never filed or
been included in any combined or consolidated Tax Return with any other person or been a member of an Affiliated Group filing a consolidated federal income Tax Return. 
  
 4.12 Real Property. The Company does not own any real property. Section 4.12 of the Disclosure Schedule lists
and describes briefly all real property leased or subleased by the Company. The Shareholder has made available to PainCare and Subsidiary correct and complete 

 copies of the leases and subleases listed in Section 4.12 of the Disclosure Schedule (as amended to date). With respect
to each lease and sublease listed in Section 4.12 of the Disclosure Schedule: 
  
 (a) Binding. The lease or sublease is legal, valid, binding, enforceable, and in full force and effect; 
  
 (b) Continued Validity. The lease or sublease will continue to be legal, valid, binding, enforceable, and in full force and effect on
identical terms following the consummation of the transactions contemplated hereby; 
  
 (c) No Defaults. The Company is not in breach or default under the lease or sublease and no third party is in breach or default under the lease or sublease, and no event has occurred which, with notice
or lapse of time, would constitute a breach or default or permit termination, modification or acceleration thereunder; 
  
 (d) Repudiation. Neither the Company nor any other party to the lease has repudiated any provision of the lease or sublease; 
  
 (e) No Disputes. There are no disputes, oral agreements, or
forbearance programs in effect as to the lease or sublease; 
  
 (f) Subleases. With respect to each sublease, the representations and warranties set forth in subsections 4.12(a) through 4.12(e) above are to Shareholder’s Knowledge true and correct with respect to the underlying lease;

  
 (g) Encumbrances. None of the Company or its
Affiliates has assigned, transferred, conveyed, mortgaged, deeded in trust, or encumbered any interest in the leasehold or subleasehold; 
  
 (h) Approvals. All facilities leased or subleased thereunder have received all approvals of governmental authorities (including licenses and
permits) required in connection with the operation thereof and have been operated and maintained in accordance with applicable laws, rules, and regulations; and 
  

(i) Utilities. All facilities leased or subleased thereunder are supplied with utilities and other services reasonably necessary for the
operation of said facilities. 
  
 4.13 Intellectual
Property. The Company owns or has the right to use pursuant to a valid license, sublicense, agreement, or permission all Intellectual Property necessary or desirable for the operation of the businesses of the Company as presently conducted
and as presently proposed to be conducted. No claim or demand of any Person has been made, nor is there any proceeding that is pending, or to the Shareholder’s Knowledge, threatened, which challenges the rights of the Company with respect to
any Intellectual Property or asserts that the Company is infringing or otherwise in conflict with or is required to pay any royalty or license fee with respect to any Intellectual Property. 

 4.14 Condition of Tangible Assets. Each tangible asset of the Company is free from defects
(patent and latent), has been maintained in accordance with normal industry practice, is in good operating condition and repair (subject to normal wear and tear), and is suitable, designed and intended for the purposes for which it presently is used
by the Shareholder and the Company. 
  
 4.15
Contracts. Section 4.15 of the Disclosure Schedule lists the following contracts and other agreements, written or oral, to which the Company was a party immediately preceding the Closing: 
  
 (a) Personal Property Leases. Any agreement (or group of
related agreements) for the lease of personal property to or from any Person providing for lease payments; 
  
 (b) Services. Any agreement (or group of related agreements) for the furnishing or receipt of services, the performance of which will extend
over a period of more than one (1) year; 
  
 (c)
Partnership; Joint Venture. Any agreement constituting a partnership or joint venture; 
  
 (d) Indebtedness. Any agreement (or group of related agreements) under which it has created, incurred, assumed, or guaranteed any
indebtedness for borrowed money, or any capitalized lease obligation; 
  
 (e) Confidentiality; Non-Competition. Any agreement concerning confidentiality or non-competition; 
  
 (f) Shareholders’ Agreements. Any agreement by and between the Shareholder and any Affiliate of the Company; 
  
 (g) Plans. Any profit sharing, stock option, stock purchase,
stock appreciation, deferred compensation, severance, or other plan or arrangement for the benefit of its current or former directors, officers, and employees; 
  

(h) Employment or Consulting Agreements. Any agreement for the employment of any individual on a full-time or part-time or the engagement
of any individual as a consultant or independent contractor, or otherwise compensating an individual for services rendered or to be rendered to the Company; 
  
 (i) Advances; Loans. Any agreement under which the Company has advanced or loaned any amount to any of its directors, officers and employees
outside the ordinary course of business; 
  
 (j) Adverse
Effects. Any agreement under which the consequences of a default or termination could have a material adverse effect on the business, financial condition, operations, results of operations or future prospects of the Company; and 

 (k) Other Agreements. Any other agreement (or group of related agreements) the performance
or rendering of which involves consideration in excess of Five Thousand and No/100 Dollars ($5,000.00). 
  
 The Shareholder has made available to PainCare and Subsidiary a correct and complete copy of each written agreement listed in Section 4.15 of the
Disclosure Schedule (as amended to date) and a written summary setting forth the terms and conditions of each oral agreement referred to in Section 4.15 of the Disclosure Schedule. With respect to each such agreement: (i) the agreement is
legal, valid, binding, enforceable, and in full force and effect; (ii) there shall be no breach or other violation resulting from the consummation of the transactions contemplated hereby; (iii) the Company is not in default or breach and no other
party is in breach or default, and no event has occurred which with notice or lapse of time would constitute a breach or default, or permit termination, modification, or acceleration, under the agreement; and (iv) neither the Company nor any other
party has repudiated any provision of the agreement. None of the agreements listed in Section 4.15 of the Disclosure Schedule requires the consent or approval of any Person, or any compensation or payment to be made to any such Person by
reason of the transactions contemplated by this Agreement, or the merger of the Company with and into another Person. 
  
 4.16 Powers of Attorney. There are no outstanding powers of attorney executed on behalf of the Company. 
  
 4.17 Insurance; Malpractice. Section 4.17 of the Disclosure
Schedule contains a list and brief description of all policies or binders of fire, liability, product liability, workers compensation, health and other forms of insurance policies or binders currently in force insuring against risks to which the
Company has been a party, a named insured or otherwise the beneficiary of coverage at any time during the five (5) years immediately preceding the Closing Date. Section 4.17 of the Disclosure Schedule contains a description of all current
malpractice liability insurance policies of the Shareholder, the Company, the New PC and the Company’s professional employees and all predecessor policies in effect. Except as set forth on Section 4.17 of the Disclosure Schedule: (a) neither
the Company, the New PC, nor its professional employees, nor the Shareholder has, during the five (5) years immediately preceding the Closing Date, filed a written application for any insurance coverage relating to the Company’s or the New
PC’s business or property which has been denied by an insurance agency or carrier; and (b) the Company, the New PC, the Company’s professional employees and the Shareholder has been continuously insured for professional malpractice claims
during the same period. Section 4.17 of the Disclosure Schedule also sets forth a list of all claims for any insured loss in excess of Five Thousand and 00/100 Dollars ($5,000) per occurrence filed by the Company, the Company’s professional
employees or the Shareholder during the five (5) years immediately preceding the Closing Date, including workers compensation, general liability, environmental liability and professional malpractice liability claims. With respect to each insurance
policy listed in Section 4.17 of the Disclosure Schedule: (i) the policy is legal, valid, binding, enforceable, and in full force and effect; (ii) the policy will continue to be legal, valid, binding, enforceable, and in full force and effect on
identical terms following the consummation of the transactions contemplated hereby; (iii) neither the Company, the New PC, the Shareholder, other health care professionals nor any other party to the policy is in breach or default (including with
respect to the payment of premiums or the giving of notices), and no event has occurred which, with notice or the lapse of 

 time, would constitute such a breach or default, or permit termination, modification, or acceleration, under the policy;
(iv) the Company has not repudiated any provision thereof and no other party to the policy has repudiated any provision thereof; (v) there is no claim pending under any of such policies as to which coverage has been questioned, denied or disputed by
the underwriter(s) of such policies or any notice that a defense will be afforded with reservation of rights; (vi) the Company has not received: (A) any notice that any issuer of any such policy has filed for protection under applicable bankruptcy
laws or is otherwise in the process of liquidating or has been liquidated; or (B) any other indication that such policies are no longer in full force and effect or that the issuer of any such policy is no longer willing or able to perform its
obligations thereunder; and (vii) the New PC, the Shareholder or the Company has not received any written notice from or on behalf of any insurance carrier issuing such policies, that there will hereafter be a cancellation, or an increase in a
deductible or non-renewal of existing policies. The Company has been covered during the past five (5) years by insurance in scope and amount customary and reasonable for the business in which it has engaged during the aforementioned period.

  
 4.18 Litigation. Except as noted in Section 4.18
of the Disclosure Schedule, there is no litigation, arbitration, governmental claim, investigation or proceeding, pending or, to Shareholder’s Knowledge, threatened, against the Company, or the Shareholder at law or in equity, before any court,
arbitration tribunal or governmental agency. Each of the Sellers has no knowledge of any facts on which claims may hereafter be made against the Company that will have a Material Adverse Effect on the Company. All medical malpractice claims, general
liability incidents and incident reports relating to the Business have been submitted to Company’s insurer. All claims made or, to Shareholder’s Knowledge, threatened against the Company or the Shareholder in excess of the deductible are
covered under the Shareholder’s or Company’s current insurance policies. Section 4.18 of the Disclosure Schedule provides a complete list of all general liability incidents, incident reports and malpractice claims relating to the Business
or the Center that have for the five (5) year period prior to the date hereof. 
  
 4.19 Health Care Compliance. The Company was, and New PC is or following application and approvals will be, participating or otherwise authorized to receive reimbursement from Medicare and Medicaid and
is a party to other third-party payor agreements set forth in Section 4.19 of the Disclosure Schedule. All necessary certifications and contracts required for participation in such programs are in full force and effect and have not been amended or
otherwise modified, rescinded, revoked or assigned, and no condition exists or event has occurred which in itself or with the giving of notice or the lapse of time or both would result in the suspension, revocation, impairment, forfeiture or
non-renewal of any such third-party payor program. The Company was, and New PC is or will be in compliance in all material respects with the requirements of all such third-party payors applicable thereto. None of the Company, New PC, its physician
employees, the Shareholder, or immediate family members of the Shareholder or other physician employees, have any financial relationship (whether investment interest, compensation interest, or otherwise) with any entity to which any of the foregoing
refer patients, except for such financial relationships that qualify for exceptions to state and federal laws restricting physician referrals to entities in which they have a financial interest. 
  
 4.20 Fraud and Abuse. The Company, New PC, the Shareholder, and
all persons and entities providing professional services in the past for the Company or presently for New PC 

 have not engaged in any activities which are prohibited under 42 U.S.C. § 1320a-7b, or the regulations promulgated
thereunder pursuant to such statutes, or related state or local statutes or regulations, or which are prohibited by rules of professional conduct, including the following: (a) knowingly and willfully making or causing to be made a false statement or
representation of a material fact in any application for any benefit or payment; (b) knowingly and willfully making or causing to be made any false statement or representation of a material fact for use in determining rights to any benefit or
payment; (c) failing to disclose Knowledge by a claimant of the occurrence of any event affecting the initial or continued right to any benefit or payment on its own behalf or on behalf of another, with intent to fraudulently secure such benefit or
payment; and (d) knowingly and willfully soliciting or receiving any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind or offering to pay or receive such remuneration: (A) in
return for referring an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part by Medicare or Medicaid; or (B) in return for purchasing, leasing, or ordering
or arranging for or recommending purchasing, leasing, or ordering any good, facility, service or item for which payment may be made in whole or in part by Medicare or Medicaid. The Company and New PC have at all times complied with the requirements
of North Dakota Statutes which prohibit physicians who have an ownership, investment or beneficial interest in certain health care facilities from referring patients to such facilities for the provisions of designated and other health services, and
has at all times complied with the North Dakota Statutes. Furthermore, the Company and New PC have filed all reports required to be filed by the State of North Dakota and federal law regarding compensation arrangements and financial relationships
between a physician and an entity to which the physician refers patients. 
  
 4.21 Legal Compliance. The Company and its predecessors and Affiliates have complied with all applicable Laws (including rules, regulations, codes, injunctions, judgments, orders, decrees, and rulings of
federal, state, local, and foreign governments (and all agencies thereof)), and no action, suit, proceeding, hearing, complaint, claim, demand, notice or investigation has been filed or commenced, or to the Knowledge of the Shareholder and the
Company, threatened against the Company alleging any failure so to comply. The Company and all physicians and other health care professionals engaged or employed by the Company (or associated with the Company as a result of being engaged or employed
by New PC) have all permits and licenses required by applicable Law, have made all required regulatory filings and are not in violation of any such permit or license. The Company was, and New PC is lawfully operated in accordance with the
requirements of all applicable Laws and had or has, respectively, in full force and effect all authorizations and permits necessary to operate a medical practice. To the Shareholder’s Knowledge, there are no outstanding notices of deficiencies
relating to the Company issued by any governmental authority or third-party payor requiring conformity or compliance with any applicable law or condition for participation with such governmental authority or third-party condition for participation
with such governmental authority or third-party payor. The Company has not received notice and the Company and Shareholder has no knowledge or reason to believe that, such necessary authorizations may be revoked or not renewed in the ordinary course
of business. To the best of Shareholder’s Knowledge, the Merger Agreement and the operation of the New PC in conjunction with the Management Agreement is in compliance with all applicable North Dakota law governing the corporate practice of
medicine. 

 4.22 Rates and Reimbursement Policies. The jurisdiction in which the Company and New PC are
located does not currently impose any restrictions or limitations on rates which may be charged to private pay patients receiving services provided by the Company except for restrictions promulgated by North Dakota law and regulation on charging of
excessive fees and limitations on charges for and profits from the sale of medications, goods and devices and free samples. The Company and New PC do not have any rate appeal currently pending before any governmental authority or any administrator
of any third-party payor program. The Company and the Shareholder have no Knowledge of any applicable Law, which affects rates or reimbursement procedures which has been enacted, promulgated or issued within the eighteen (18) months preceding the
date of this Agreement or any such legal requirement proposed or currently pending in the State of North Dakota which could have a Material Adverse Effect on the Company, New PC, their businesses or operations, or may result in the imposition of
additional Medicaid, Medicare, charity, free care, welfare, or other discounted or government assisted patients at New PC or require New PC to obtain any necessary authorization which New PC does not currently possess. Neither the Company nor the
Shareholder have Knowledge of any impending proposed reduction in reimbursement from third party or other payors nor Knowledge of any threatened termination of payor contracts. 
  
 4.23 Medical Staff. Except as set forth on Section 4.23 of the Disclosure Schedule, the Shareholder has no
Knowledge of a physician who is providing services on behalf of the Company or New PC who plans, or has threatened to terminate his or her employment or other relationship with the Company. To the Knowledge of the Company and the Shareholder, none
of the physicians who are providing services on behalf of New PC or who provided services on behalf of the Company currently has plans to retire from the practice of medicine in the next three (3) years. 
  
 4.24 Employees. Except as set forth on Section 4.24 of the
Disclosure Schedule: (a) there is no unfair labor practice charge or complaint pending or, to the Knowledge of the Company and the Shareholder, threatened relating to the business of the Company; and (b) payment in full to all of the employees of
the Company of all wages, salaries, commissions, bonuses, benefits, and other compensation lawfully due and owing to such employees or otherwise arising under any policy, practice, agreement, plan, program, statute, or other law as of the Closing
Date has been made. 
  
 4.25 Employee Benefits.

  
 (a) Plans. Section 4.25 of the Disclosure
Schedule lists each Employee Benefit or health and welfare plan that the Company maintains or to which the Company contributes, and describes any qualifications to the representations set forth in this Section 4.25. 
  
 (b) Compliance. Each such Employee Benefit Plan (and each
related trust, insurance contract, or fund) complies in form and in operation in all material respects with its terms and with the applicable requirements of ERISA, the Code and other applicable laws. 
  
 (c) Reports and Descriptions. All required reports and
descriptions (including Form 5500 Annual Reports, Summary Annual Reports, PBGC-1’s, and Summary Plan Descriptions) have been filed or distributed appropriately with respect to each such 

 Employee Benefit Plan. The requirements of Part 6 of Subtitle B of Title I of ERISA and of Code Section 4980B have been
met with respect to each such Employee Benefit Plan which is an Employee Welfare Benefit Plan. 
  
 (d) Contributions. All contributions (including all employer contributions and employee salary reduction contributions) which are due have been paid to each such Employee Benefit Plan which is an
Employee Pension Benefit Plan and all contributions for any pay period ending on or before the Closing Date which are not yet due have been paid to each such Employee Pension Benefit Plan or accrued in accordance with the past custom and practice of
the Company. All premiums or other payments due for all periods ending on or before the Closing Date have been paid with respect to each such Employee Benefit Plan which is an Employee Welfare Benefit Plan. 
  
 (e) Qualified Plan. Each such Employee Benefit Plan which is an
Employee Pension Benefit Plan and is intended to meet the requirements of a “qualified plan” under Code Section 401(a) meets such requirements and has received, within the last two (2) years, a favorable determination letter from the IRS.

  
 (f) Market Value. The market value of assets
under each such Employee Benefit Plan which is an Employee Pension Benefit Plan (other than any Multiemployer Plan) equals or exceeds the present value of all vested and nonvested Liabilities thereunder determined in accordance with PBGC methods,
factors, and assumptions applicable to an Employee Pension Benefit Plan terminating on the date for determination. 
  
 (g) Copies. The Shareholder has delivered to PainCare and Subsidiary correct and complete copies of the plan documents and summary plan
descriptions, the most recent determination letter received from the IRS, the most recent Form 5500 Annual Report, and all related trust agreements, insurance contracts, and other funding agreements which implement each such Employee Benefit Plan.

  
 (h) Maintenance of Plans. With respect to each
Employee Benefit Plan that the Company maintains, ever has maintained, or to which it contributes, ever has contributed, or ever has been required to contribute: 
  
 (i) Reportable Events. No such Employee Benefit Plan which is an Employee Pension Benefit Plan has been
completely or partially terminated or been the subject of a Reportable Event as to which notices would be required to be filed with the PBGC. No proceeding by the PBGC to terminate any such Employee Pension Benefit Plan has been instituted or
threatened; and 
  
 (j) Prohibited Transactions.
There have been no Prohibited Transactions with respect to any such Employee Benefit Plan. No Fiduciary has any Liability for breach of fiduciary duty or any other failure to act or comply in connection with the administration or investment of the
assets of any such Employee Benefit Plan. No action, suit, proceeding, hearing, or investigation with respect to the administration or the investment of the assets of any such Employee Benefit Plan (other than any Multiemployer Plan), other than
routine claims for benefits, is pending or threatened. The Shareholder and the Company have no Knowledge of any basis for any such action, suit, proceeding, hearing, or investigation. 

 4.26 Physicians and Other Providers. During the five (5) years preceding the Closing Date,
each physician, and other health care provider who is or was employed by, or who renders or has rendered services on behalf of, the Company or New PC: 
  
 (a) Licenses. Has been duly licensed and registered, and in good standing by the State of North Dakota to engage in the practice of
medicine, and said license and registration have not been suspended, revoked or restricted in any manner; 
  
 (b) Controlled Substances. Has current controlled substances registrations issued by the State of North Dakota and the U.S. Drug Enforcement
Administration, which registrations have not been surrendered, suspended, revoked or restricted in any manner; 
  
 (c) Actions. Except as set forth on Section 4.26 of the Disclosure Schedule, has not been a party or subject to: 
  
 (i) Malpractice Actions. Any malpractice suit, claim (whether
or not filed in court), settlement, settlement allocation, judgment, verdict or decree; 
  
 (ii) Disciplinary Proceedings. Any disciplinary, peer review or professional review investigation, proceeding or action instituted by any licensure board, hospital, medical school, physical therapy
school, health care facility or entity, professional society or association, third party payor, peer review or professional review committee or body, or governmental agency; 
  
 (iii) Criminal Proceedings. Any criminal complaint, indictment or criminal proceedings; 
  
 (iv) Investigation. Any investigation or proceedings, whether
administrative, civil or criminal, relating to an allegation of filing false health care claims, violating anti-kickback or fee-splitting laws, or engaging in other billing improprieties; 
  
 (v) Mental Illnesses. Any organic or mental illness or condition that impairs or may impair such
physician’s ability to practice; 
  
 (vi) Substance
Abuse. Any dependency on, habitual use or episodic abuse of alcohol or controlled substances, or any participation in any alcohol or controlled substance detoxification, treatment, recovery, rehabilitation, counseling, screening or
monitoring program; 
  
 (vii) Professional Ethics.
Any allegation, or any investigation or proceeding based on any allegation of violating professional ethics or standards, or engaging in illegal, immoral or other misconduct (of any nature or degree), relating to his or her practice; or 

 
 (viii) Application for Licensure. Any denial or withdrawal
of an application in any state for licensure as a physician or physical therapist, for medical staff privileges at any hospital or other health care entity, for board certification or recertification, for participation in any third party payment
program, for state or federal controlled substances registration, or for malpractice insurance. 

 4.27 Guaranties. Saving the guaranties listed in Section 4.27 of the Disclosure Schedule,
the Company is not a guarantor or otherwise liable for any Liability or obligation (including indebtedness) of any other Person. 
  
 4.28 Environment, Health, and Safety. 
  
 (a) Compliance. Each of the Company and its predecessors and Affiliates has complied and is in material compliance with all Environmental,
Health, and Safety Requirements. 
  
 (b) Permits and
Licenses. Without limiting the generality of the foregoing, each of the Company and its Affiliates has obtained and complied in all material respects with, and is in compliance in all material respects with, all permits, licenses and other
authorizations that are required pursuant to Environmental, Health, and Safety Requirements for the occupation of its facilities and the operation of its business; a list of all such permits, licenses and other authorizations is set forth on Section
4.28 of the Disclosure Schedule. 
  
 (c) Notices.
None of the Company nor its predecessors or Affiliates has received any written or oral notice, report or other information regarding any actual or alleged violation of Environmental, Health, and Safety Requirements, or any Liabilities or potential
Liabilities (whether accrued, absolute, contingent, unliquidated or otherwise), including any investigatory, remedial or corrective obligations, relating to any of them or its facilities arising under Environmental, Health, and Safety Requirements.

  
 (d) Hazardous Substances. None of the Company or
its predecessors or Affiliates has treated, stored, disposed of, arranged for or permitted the disposal of, transported, handled, or released any substance, including without limitation any hazardous substance, or owned or operated any property or
facility (and no such property or facility is contaminated by any such substance) in a manner that has given or would give rise to liabilities, including any Liability for response costs, corrective action costs, personal injury, property damage,
natural resources damages or attorney fees, pursuant to the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, the Solid Waste Disposal Act, as amended or any other Environmental, Health, and Safety
Requirements. 
  
 (e) The Company has not received any
communication (written or oral), whether from a governmental authority, citizens’ group, employee or otherwise, that alleges that the Business or the Company is not in full compliance with Environmental Laws, or that the Company is otherwise
subject to liability under Environmental Laws, and to the Shareholder’s Knowledge, there are no circumstances that may prevent or interfere with such full compliance in the future. There is no Environmental Claim (as defined below) pending or,
to the Shareholder’s Knowledge, threatened against the Company, the Business or the Center. 
  
 (f) The Shareholder has no Knowledge of any actions, activities, circumstances, conditions, events or incidents, including, but not limited to, the
release, emission, discharge, presence or disposal of any Hazardous Substances that could form the basis of any Environmental Claim against the Company, the Business or the Center, or Sellers in connection with the Business or the Center.

 4.29 Certain Business Relationships with the Company and its Affiliates. Except as
contemplated hereby with respect to New PC, neither the Shareholder nor any of his Affiliates have been involved in any business arrangement or relationship with the Company and its Affiliates within the past twelve (12) months, and none of the
Shareholder and his Affiliates owns any asset, tangible or intangible, which is material to the business of any of the Company and its Affiliates. 
  
 4.30 Third-party Payors. Section 4.30 of the Disclosure Schedule sets forth an accurate, correct and complete list of the Company’s
third-party payors. Neither the Company nor the Shareholder has received any notice nor has any Knowledge that any third-party payor intends to terminate or materially reduce its business with, or reimbursement to, the New PC. The Company has no
reason to believe that any third-party payor will cease to do business with the New PC after, or as a result of, the consummation of any transactions contemplated hereby. The Company does not know of any fact, condition or event which would
adversely affect the New PC’s relationship with any third-party payor. 
  
 4.31 Bank Accounts. Section 4.31 of the Disclosure Schedule sets forth all of the bank and security accounts and all safe deposit boxes maintained by the Company and all lines of credit owned or used by
the Company, and the names of all persons with authority to withdraw funds from, or execute drafts or checks on, each such account. 
  
 4.32 Tax Status. The Shareholder is not a “nonresident alien individual” or “foreign corporation” for purposes of Code
Section 897(a)(1). 
  
 4.33 Binding Obligation. This
Agreement constitutes the valid and legally binding obligation of the Shareholder, enforceable in accordance with its terms and conditions. 
  
 4.34 No Corporate Practice or Fee Splitting. The Shareholder does not have any Knowledge that the actions, transactions or relationships
arising from, and contemplated by, the Transaction violate any law, rule or regulation relating to the corporate practice of medicine or fee splitting. The Shareholder accordingly agrees that he will not and will not cause any other Party, in an
attempt to void or nullify this Agreement or any document related to the Transaction or any relationship involving PainCare or Subsidiary to sue, claim, aver, allege or assert that any such document or any such relationship violates any law, rule or
regulation relating to the corporate practice of medicine or fee splitting, subject, however, to the provisions of Sections 2.6 and 11.7 of the Management Agreement. 
  
 4.35 Intentions. The Shareholder intends to continue managing the business operations of the New PC on a
full-time basis for the next (3) years and does not know of any fact or condition that adversely affects, or in the future may adversely effect, his ability or intention to manage the business of the New PC on a full-time basis for the next three
(3) years. 
  
 4.36 Securities Representation.

  
 (a) No Registration of PainCare Shares; Investment
Intent. The Shareholder acknowledges that the PainCare Shares to be delivered pursuant to this Agreement have not been and will not be registered under the Securities Act and may not be resold without compliance with the Securities Act. The
PainCare Shares are not registered but are governed by 

 
Rule 144 promulgated under the 1933 Act. Subject to the conditions and restrictions set forth in Rule 144, PainCare agrees that the PainCare Shares will be
freely transferable upon the expiration of one year and will be freely transferable by the Shareholder following the first anniversary of closing under this agreement. The PainCare Shares to be acquired by the Shareholder pursuant to this Agreement
are being acquired solely for his own account, for investment purposes only and with no present intention of distributing, selling or otherwise disposing of them in connection with a distribution other than in compliance with the Securities Act.

  
 (b) Resale Restrictions. The Shareholder
covenants, warrants and represents that none of the PainCare Shares issued to Shareholder will be offered, sold, assigned, pledged, hypothecated, transferred or otherwise disposed of except after full compliance with all of the applicable provisions
of the Securities Act and the rules of regulations of the Commission and applicable state securities laws, and the applicable provisions of any PainCare Stockholders’ Agreement and this Agreement. All certificates evidencing the PainCare Shares
shall bear the legends contained in the PainCare Stockholders’ Agreement. 
  
 (c) Ability to Bear Economic Risk. The Shareholder covenants, warrants and represents that he is able to bear the economic risk of an investment in the PainCare Shares acquired pursuant to this Agreement
and can afford to sustain a total loss of such investment and has such Knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the proposed investment and therefore has the capacity to
protect his own interests in connection with the acquisition of the PainCare Shares. The Shareholder, and the Shareholder’s purchaser representative, if any, have received copies of PainCare’s most recent 10-K, 10-Q AND 8-K filings and
have had an adequate opportunity to ask questions and receive answers from the officers of PainCare concerning any and all matters relating to the background and experience of the officers and directors of PainCare, the plans for the operations of
the business of PainCare, and any plans for additional acquisitions and the like. The Shareholder, and the Shareholder’s purchaser representative, if any, have asked any and all questions in the nature described in the preceding sentence and
all questions have been answered to such individual’s satisfaction. 
  
 (d) Accredited Investor. The Shareholder covenants, represents and warrants that he is an: (a) individual with a net worth (either individually or jointly with his respective spouse) in excess of One
Million and No/100 Dollars ($1,000,000.00); or (b) individual who had an income in excess of Two Hundred Thousand and No/100 Dollars ($200,000.00) in each of 2001 and 2002, or had a joint income with his spouse in excess of Three Hundred Thousand
and No/100 Dollars ($300,000.00) in each of 2001 and 2002, and has a reasonable expectation of reaching the same income level in 2003. 
  
 (e) Residency. The Shareholder covenants, warrants and represents that he is a resident of the State of North Dakota, and received this
Agreement and first learned of the transactions contemplated hereby in the State of North Dakota. He executed and will execute all documents contemplated hereby in the State of North Dakota, and intends that the laws of the State of North Dakota
govern this transaction. 

 (f) No Registration. The Shareholder understands, agrees and acknowledges that the PainCare
Shares have not been registered under the North Dakota Securities Act or the Securities Act in reliance upon exemption provisions contained therein which PainCare believes are available. 
  
 4.37 HIPAA. Schedule 4.37 lists and describes all plans and other efforts of the Shareholder with respect to
the practice locations to comply with the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), including the final regulations promulgated thereunder, whether such plans and efforts have been put in place or are in
process. Schedule 4.37 includes but is not limited in any manner whatsoever to any privacy compliance plan of Sellers in place or in development, and any plans, analyses or budgets relating to information systems including but not limited to
necessary purchases, upgrades or modifications to effect HIPAA compliance. 
  
 4.38 Improper and Other Payments. (a) Neither the Company, any director, officer, employee thereof, nor any agent or representative of the Company nor any person acting on behalf of any of them, has
made, paid or received any unlawful bribes, kickbacks or other similar payments to or from any person or authority, (b) no contributions have been made, directly or indirectly, by the Company to a domestic or foreign political party or candidate;
and (c) the internal accounting controls of the Company are believed by the Company’s management to be adequate to detect any of the foregoing under current circumstances. 
  
 4.39 Accounts Receivable. Schedule 4.39 sets forth a list, accurate, correct and complete in all respects, of
all outstanding accounts and notes receivable of the Company as of the last day of the month immediately preceding the Execution Date (which will be updated as of the Closing to the last day of the month immediately preceding the Closing Date). All
outstanding accounts and notes receivable reflected on Schedule 4.39 are due and valid claims against account debtors for services rendered in accordance with the usual business practices and historical collection experience of the Company and to
the best of Shareholder’s knowledge are subject to no counterclaims, and have been outstanding for the periods indicated in the aging analysis at Schedule 4.39. The Shareholder know of no reason why such accounts receivable would not be
collectible by the Company according to approximately the same ratios as accounts receivable have been historically collectible by the Company. All outstanding accounts and notes receivable included on Schedule 4.39 arose in the ordinary course of
business. 
  
 4.40 Medical Waste. With respect to
the generation, transportation, treatment, storage, and disposal, or other handling of Medical Waste, the Company has complied with all Medical Waste Laws (as hereinafter defined). 
  
 “Medical Waste” includes, but is not limited to, (a) pathological waste, (b) blood, (c) sharps, (d) wastes from surgery or
autopsy, (e) dialysis waste, including contaminated disposable equipment and supplies, (f) cultures and stocks of infectious agents and associated biological agents, (g) contaminated animals, (h) isolation wastes, (i) contaminated equipment, (j)
laboratory waste, and (k) various other biological waste and discarded materials contaminated with or exposed to blood, excretion, or secretions from human beings or animals. “Medical Waste” also includes any substance, pollutant,
material, or contaminant listed or regulated under the Medical Waste Tracking Act of 1988, 42 U.S.C. §§6992, et seq. (“MWTA”). 

 “Medical Waste Law” means the following, including regulations promulgated and orders issued thereunder, all as
may be amended from time to time: the MWTA; the U.S. Public Vessel Medical Waste Anti-Dumping Act of 1988, 33 USCA §§2501 et seq.; the Marine Protection, Research, and Sanctuaries Act of 1972, 33 USCA §§1401 et seq.; the
Occupational Safety and Health Act, 29 USCA §§651 et seq.; the United States Department of Health and Human Services, National Institute for Occupational Self-Safety and Health Infectious Waste Disposal Guidelines, Publication No. 88-119;
and any other federal, state, regional, county, municipal, or other local laws, regulations, and ordinances insofar as they purport to regulate Medical Waste, or impose requirements relating to Medical Waste. 
  
 4.41 No Untrue or Inaccurate Representation or Warranty. No
representation or warranty by Sellers contains or will contain any untrue statement of fact, or omits or will omit to state a fact necessary to make the statements and information contained in this Section 4 not misleading in any material respect.

  
 5. REPRESENTATIONS AND WARRANTIES OF THE ACQUIRING COMPANIES.
The Acquiring Companies represent and warrant to the Shareholder that the statements contained in this Section 5 are correct and complete as of the Closing Date. 
  
 5.1 Organization of PainCare and Subsidiary. PainCare is a corporation duly organized, validly existing, and
in good standing under the laws of the State of Florida. Subsidiary is a corporation duly organized, validly existing and in good standing under the laws of the State of Florida. 
  
 5.2 Authorization of Transaction. PainCare and Subsidiary have full power and authority (including full
corporate power and authority) to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement constitutes the valid and legally binding obligation of PainCare, enforceable in accordance with its terms and conditions.
The execution and delivery of this Agreement has been approved and authorized by the Board of Directors of PainCare. 
  
 5.3 No Conflict or Violation. Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated
hereby will result in (a) a violation of or a conflict with any provision of the Certificate or Articles of Incorporation or bylaws of PainCare or Subsidiary, (b) a breach of, or a default under, any term or provision of any contract, agreement,
indebtedness, lease, commitment, license, franchise, permit, authorization or concession to which PainCare or Subsidiary is a party, which breach or default could reasonably be expected to have a Company material adverse effect on the business or
financial condition of PainCare or Subsidiary or its ability to consummate the transactions contemplated hereby or (c) a violation by PainCare or Subsidiary of any statute, rule, regulation, ordinance, code, order, judgment, writ, injunction, decree
or award, which violation could reasonably be expected to have a material adverse effect on the business or financial condition of PainCare or Subsidiary, or their ability to consummate the transactions contemplated hereby. 
  
 5.4 Consents and Approvals. Except as set forth on
Disclosure Schedule 5.4, no notice to, declaration, filing or registration with, or authorization, consent or approval of, or permit from, any domestic or foreign governmental or regulatory body or authority, or any other person or entity, is
required to be made or obtained by PainCare or Subsidiary in connection with the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby. 

 5.5 Disclosure Documents. PainCare has delivered or Stockholder has had the opportunity to
obtain and review PainCare’s Form 10-KSB for the year ending December 31, 2002, Form S-4/A filed with the SEC on July 11, 2002, Form 10-QSB for the period ending September 30, 2003 filed with the SEC on November 12, 2003, Form 14A (Definitive
Proxy) filed with the SEC on September 17, 2002 and current Forms 8-K (the “PainCare Disclosure Documents”). The PainCare Disclosure Documents are true and correct in all material respects and do not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements therein, in light of the circumstances under which such statements were made, not misleading. To the knowledge of PainCare nothing has occurred after the date
of the documents contained in the Disclosure Documents that would individually or in the aggregate have a material adverse effect on PainCare. 
  
 5.6 Capitalization. The authorized capital stock of PainCare consists of 75,000,000 shares of Common Stock, $.0001 par value per share,
which as of November 7, 2003, approximately 23,747,662 shares are issued and outstanding, 10,000,000 shares of “blank check” preferred none of which have been issued or are outstanding. All of the PainCare Shares are, and all shares of the
PainCare Shares to be issued pursuant to this Agreement will be, validly issued, fully paid and non-assessable. Disclosure Schedule 5.6(a) hereto sets forth a listing of all options, warrants and outstanding PainCare securities which are convertible
(with or without the payment of consideration) into shares of the Common Stock of PainCare, including all contingently issuable shares of such Common Stock issuable pursuant to agreements outstanding as of June 30, 2003. Disclosure Schedule 5.6(b)
also sets forth the terms of any financing proposed to be raised by PainCare in connection with the transactions contemplated by this Agreement. 
  
 5.7 Litigation. Except as set forth in Disclosure Schedule 5.7, there is no charge, complaint, action, order, writ, injunction, judgment or
decree outstanding or claim, suit, litigation, proceeding, labor dispute, arbitrable action or investigation (collectively, “Actions”) pending or, to the knowledge of PainCare, threatened against, relating to or affecting (i) PainCare or
its assets or the operation of the business of PainCare as currently operated and as proposed to be operated, (ii) any Employee Plan of PainCare or any trust or other funding instrument, fiduciary or administrator thereof or (iii) the transactions
contemplated by this Agreement, before or by any federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, any of which is reasonably expected to result in a loss not
covered by insurance in excess of $100,000 or reasonably expected to have a material adverse effect on PainCare. To the knowledge of PainCare, PainCare is not in default with respect to any judgment, order, writ, injunction or decree of any court or
governmental agency, and there are no unsatisfied judgments against PainCare or the business of PainCare. Except as set forth in Disclosure Schedule 5.7, each Action pending or, to the knowledge of PainCare, threatened (whether or not disclosed in
Disclosure Schedule 5.7), is covered by insurance of reputable and solvent insurance companies. 
  
 5.8 No Undisclosed Liabilities. Except as set forth in Disclosure Schedule 5.8, to the knowledge of PainCare, PainCare has no liabilities or
obligations (absolute, accrued, contingent or otherwise) except (i) liabilities that are reflected and reserved against on PainCare’s audited 

 balance sheet dated December 31, 2002 (the “PainCare Balance Sheet Date”) that have not been paid or discharged
since the date thereof and (ii) liabilities incurred by PainCare since PainCare Balance Sheet Date in the ordinary course of business consistent with past practice (none of which relates to any breach of contract, breach of warranty, tort,
infringement or violation of law or arose out of any complaint, action, suit or proceeding except those which individually or in the aggregate could not have a material adverse effect on PainCare). 
  
 5.9 No Brokers. There is no obligation on the part of PainCare to pay
any finder’s fee, brokerage commission or similar payment in connection with the transactions contemplated hereby. 
  
 5.10 Material Misstatements Or Omissions. To the knowledge of PainCare, no representations or warranties by PainCare in this Agreement, nor any
document, exhibit, statement, certificate or schedule furnished or to be furnished to the Shareholder pursuant hereto, or in connection with the transactions contemplated hereby, contains or will contain any untrue statement of a material fact, or
omits or will omit to state any material fact necessary to make the statements or facts contained therein not misleading. 
  
 5.11 No Corporate Practice or Fee Splitting. PainCare does not have any Knowledge that the actions, transactions or relationships arising from, and
contemplated by, the Transaction violate any law, rule or regulation relating to the corporate practice of medicine or fee splitting. PainCare accordingly agrees that he will not and will not cause any other Party, in an attempt to void or nullify
this Agreement or any document related to the Transaction or any relationship involving the Company or the Shareholder to sue, claim, aver, allege or assert that any such document or any such relationship violates any law, rule or regulation
relating to the corporate practice of medicine or fee splitting, subject, however, to the provisions of Sections 2.6 and 11.7 of the Management Agreement. 
  
 6. CLOSING; TERMINATION. The closing of the Transaction (the “Closing”) shall take place via remote location as coordinated by the Parties’
respective counsel commencing at 10:00 a.m. Eastern Daylight Time on or about December 17 (the “Closing Date”). In the event that the Closing has not occurred on or before December 31, 2003, this Agreement may be terminated by either Party
provided such Party has, as of the date of such election to terminate, fulfilled all conditions to the obligations of the other Party. In the event that Closing does not occur by January 15, 2004, this Agreement shall terminate unless the Parties
otherwise agree in writing. 
  
 7. CLOSING DELIVERIES. 
  
 7.1 Deliveries of the Company and the Shareholder. At or prior to the
Closing, the Company and the Shareholder shall deliver to the Acquiring Companies the following: 
  
 (a) Consents and Approvals. Copies of all authorizations, consents, and approvals of governments, governmental agencies and third parties referred
to in Section 4.4(a) of the Disclosure Schedule; 
  
 (b)
Termination of Agreements. Copies of documents effectuating the termination of any and all written employment and independent contractor agreements, compensation agreements, buy-sell agreements and other similar agreements entered into
by the 

 Company and which are in effect immediately preceding the Closing, which terminations shall each include a complete
release of the Company from all known or unknown obligations or liabilities; 
  
 (c) Company Stock. The Certificates and stock powers, duly endorsed, transferring the Company Stock to Subsidiary and the officer and director resignations required in Section 4.6; 
  
 (d) Corporate Authorization. A certified copy of resolution(s)
of the Shareholder and board of directors of the Company which authorizes the Transaction in accordance with: (a) applicable law; (b) the Company’s articles of incorporation and bylaws; and (c) all other requirements for proper corporate
authorization; 
  
 (e) Payoffs. Payoff letters from
those creditors listed in Section 7.1(e) of the Disclosure Schedules; 
  
 (f) Good Standing Certificate. A certificate issued by the appropriate state governmental authority no more than ten (10) days prior to the Closing Date evidencing the good standing of the Company and the New PC; 

 
 (g) Secretary’s Certificate. A certificate of the
secretary of the Company and the New PC certifying that the minute books, articles of incorporation and bylaws of the Company and the New PC, attached as exhibits to such certificate, are true, correct, and complete; 
  
 (h) Medicare Provider Number. A copy of the completed
application for New PC’s Medicare provider number signed by Shareholder together with Shareholder’s certification that such application has been filed; 
  
 (i) Lease. The Lease for the premises, fully executed; and 
  
 (j) Other documents. Such other instruments or documents as may
be necessary or appropriate to carry out the Transactions. 
  
 7.2
Deliveries of PainCare. At the Closing, PainCare shall deliver to the Shareholder the following: 
  
 (a) Transaction Consideration. The Transaction Consideration; 
  
 (b) Resolutions. A certified copy of the resolution of the board of directors of PainCare, and the sole
shareholder and members of the board of directors of Subsidiary, authorizing the Transaction; 
  
 (c) Lease. The Lease for the premises, fully executed; and 
  
 (d) Other documents. Such other instruments or documents as may be necessary or appropriate to carry out the Transactions. 

 8. CONDITIONS TO THE OBLIGATIONS OF THE PARTIES. The obligations of the Parties to Close are subject to the
satisfaction of the following respective conditions unless waived by the Party for whose benefit the condition applies. 
  
 8.1 Conditions for the Benefit of PainCare and the Subsidiary. (a) The representations and warranties of the Shareholder and the Company in
this Agreement and all information contained in any exhibit, certificate, schedule or attachment hereto or in any writing delivered by, or on behalf of the Shareholder or the Company shall be true and correct when made and shall be true and correct
in all material respects on the Closing Date as though then made, except as expressly provided for herein, and (b) both the Shareholder and the Company shall have performed and complied with all agreements, covenants and conditions and shall have
made all deliveries required by this Agreement to be performed, delivered and complied with by them prior to the Closing Date; and (c) New PC shall have filed an application for a Medicare provider number to obtain payment or reimbursement for its
services, and (d) New PC shall notify its payors of its business operations, and (e) PainCare has closed on a capital raise of not less than $5,000,000. 
  
 8.2 Conditions for the Benefit of the Shareholder. (a) The representations and warranties of PainCare in this Agreement and all information
contained in any exhibit, certificate, schedule or attachment hereto or in any writing delivered by, or on behalf of PainCare or the Subsidiary shall be true and correct when made and shall be true and correct in all material respects on the Closing
Date as though then made, except as expressly provided for herein, and (b) both the Shareholder and the Company shall have performed and complied with all agreements, covenants and conditions and shall have made all deliveries required by this
Agreement to be performed, delivered and complied with by them prior to the Closing Date; and (c) New PC shall have applied for a Medicare provider number to obtain payment and reimbursement for its services; and (d) the Fair Market Value of the
PainCare Shares shall not be as calculated on the day immediately preceding the Closing less than $2.10 per share. 
  
 9. COVENANTS. The Parties covenant and agree as follows with respect to the period following the Execution Date: 
  
 9.1 Operations Pending Closing. Simultaneously with the
execution of this Agreement, the Company, New PC and the Subsidiary are executing and delivering the Management Agreement and the Shareholder and the New PC are executing and delivering the Employment Agreement. Pending the Effective Date, the
Shareholder shall be designated by the Subsidiary as the Medical Group Administrator under the Management Agreement. 
  
 9.2 Deliveries Pending Closing. PainCare will promptly deliver and make available to Shareholder copies of any filings made by it under the
Securities Act or the Securities Exchange Act, including the exhibits thereto and any correspondence with the Securities Exchange Commission or its staff. 
  
 9.3 Distributions of Sub-Chapter S Income by the Company. Not later than the Closing Date, one hundred percent (100%) of the taxable income
(as determined by using the cash method of accounting) allocated to Shareholder for the period beginning on January 1, 2003 and ending on the Execution Date shall have been distributed to the Shareholder subject to the 

 requirement that Shareholder shall insure that as of the Closing Date that the Company will have a minimum cash balance
of Twenty Thousand Dollars ($20,000). The Shareholder shall not be entitled to any additional distributions or payments with respect to taxable income of the Company (i) for the period ending December 31, 2002; (ii) for the period beginning on the
Execution Date and ending on the Closing Date; or (iii) after the Closing Date for any reasons whatsoever, other than as specifically set forth in this Agreement. 
  
 9.4 Post-Closing General Covenant. In the event that at any time after the Closing any further action is
necessary to carry out the purposes of this Agreement, each of the Parties will take such further action (including the execution and delivery of such further instruments and documents) as any other Party may reasonably request, all at the sole cost
and expense of the requesting Party; provided, however, that the costs and expenses associated with the taking of any action necessary to execute or deliver to PainCare any stock powers and such other instruments of transfer as may be necessary to
transfer ownership of the Company’s Shares by the Shareholder shall be borne by the Shareholder. 
  
 9.5 Tax Returns. The Shareholder shall be responsible for preparing and filing all income or franchise Tax Returns of the Company relating
to periods of time prior to the Closing Date. PainCare and the Subsidiary will provide to the Shareholder access to all books and records of the Company necessary to the preparation of such Tax Returns and the Subsidiary, as the successor to the
Company will execute such Tax Returns. The Shareholder will take no positions on the Tax Returns of the Company that relate to the tax period prior to the Closing Date that could adversely affect the Company or PainCare after the Closing. The
Shareholder will provide PainCare with an opportunity to review and comment on such Tax Returns (including any amended returns). PainCare will be responsible for preparing and filing all income and franchise Tax Returns of the Company relating to
periods after the Closing. The income of the Company will be apportioned to the period up to the Closing Date and the period from and after the Closing Date in accordance with the provisions of Code Section 1362(e)(6)(D) by closing the books of the
Company as of the close of business on the last calendar day immediately preceding the Closing Date, with recognition that the Company files on that basis of a cash rather than accrual method. The Acquiring Companies shall be solely responsible for
any taxes due arising from conversion from the cash to the accrual method of accounting, including but not limited to tax due on the realization of income from accounts receivable recorded prior to closing. 
  
 9.6 Transition. Neither the Shareholder nor the Company will
take any action that is designed, intended or likely to have the effect of discouraging any lessor, licensor, customer, supplier or other business associate of the Company from maintaining the same business relationships with the Company after the
Closing as he, she or it maintained with the Company prior to the Closing. 
  
 9.7 Litigation Support. In the event and for so long as any Party actively is contesting or defending against any action, suit, proceeding, hearing, investigation, charge, complaint, claim or demand in
connection with: (a) any transaction contemplated under this Agreement; or (b) any fact, situation, circumstances, status, condition, activity, practice, occurrence, event, incident, action, failure to act, or transaction on or prior to the Closing
Date involving the Company, each of the Parties will cooperate with the contesting or defending Party 

 and its or his counsel in the contest or defense, at the sole cost and expense of the contesting or defending Party
except to the extent that the contesting or defending party is entitled to indemnification therefor under this Agreement. 
  
 9.8 Consents. The Shareholder hereby covenants and agrees that, after the Execution Date, he will use his best efforts to obtain all
authorizations, consents, and approvals set forth in Section 4.4(b) of the Disclosure Schedule. If such consent, approval or agreement is not obtained, or if an attempted assignment thereof would affect the rights of the parties thereunder so that
such parties would not in fact receive all such rights, the Parties will cooperate in any arrangement designed to provide for the Parties to receive the benefits under any such contract, including enforcement for the benefit of PainCare and
Subsidiary of any and all rights of the Shareholder against a third party thereto arising out of the breach or cancellation by such third party or otherwise. 
  
 9.9 Operational Covenants. Without the prior written consent of Shareholder, which shall not be unreasonably withheld, PainCare shall not,
prior to the conclusion of the third Formula Period: 
  
 (a)
reorganize the Surviving Corporation, whether by integrating or consolidating the business of the Surviving Corporation with other operating units of PainCare or its subsidiaries or affiliates, except in the case that at the time of such integration
or consolidation such transaction could not reasonably be expected to have a material adverse effect on the Formula Period Profits; 
  
 (b) effect any reassignment, reprioritization, reallocation, restructuring, or reduction of the Surviving Corporation’s human or other resources,
their research and development initiatives, or their marketing programs, except in a manner that at the time of such event could not reasonably be expected to have a material adverse effect on the Formula Period Profits or that are reasonably
necessary in light of the Surviving Corporation’s results of operation; 
  
 (c) amend the articles of incorporation or bylaws of the Surviving Corporation in any manner that at the time of such amendment could reasonably be expected to have a material adverse effect on the Formula Period
Profits; 
  
 (d) cause the Surviving Corporation to become a party
to or terminate any agreement which at the time such agreement is entered into or terminated could reasonably be expected to have a material adverse effect on the Formula Period Profits or that is reasonably necessary in light of the Surviving
Corporation’s results of operation; 
  
 (e) cause the
Surviving Corporation to undertake actions outside the ordinary course of its business which at the time of such undertaking could reasonably be expected to have a material adverse effect on the Formula Period Profits; 
  
 (f) sell a material portion of the Surviving Corporation or its assets, merge
the Surviving Corporation with any other entity, sell a controlling interest in the Surviving Corporation, or make any fundamental change in the business of the Surviving Corporation unless such action(s) at the time of such undertaking could not
reasonably be expected to have a material adverse effect on the Formula Period Profits or that is reasonably necessary in light of the Surviving Corporation’s results of operation; 

 The parties hereby acknowledge and agree that the foregoing covenants in this Section 9.9 shall become
null and void and of no further force or effect if the Formula Period Profits of the Surviving Corporation in each of any two (2) consecutive calendar quarters are less than $150,000, or if the Formula Period Profits of the Surviving Corporation in
one (1) calendar quarter is less than $75,000. 
  
 9.10
Capital Adjustments. In the event of a stock dividend, recapitalization, or merger in which PainCare is the surviving corporation, split-up, combination or exchange of shares or the like which results in a change in the number or kind
of shares of common stock which is outstanding immediately prior to such event, the rights of the Shareholder to receive the PainCare Shares in respect of this Agreement and the price thereof, shall be appropriately adjusted in the same manner as
the number and kind of shares a shareholder of PainCare who owned the same number and kind of shares immediately prior to such event. Such adjustments shall be made in good faith by the Board of Directors of PainCare, whose determination shall be
conclusive and binding on all parties, subject to manifest error. 
  
 In case of any consolidation or merger of PainCare with or into another party or parties or the conveyance of all or substantially all of the assets of PainCare to another party or parties or a share exchange transaction involving more than
50% of the issued and outstanding common stock of PainCare, the PainCare Shares and right to receive the PainCare Shares shall thereafter be convertible into the number of shares of stock, options or other securities or property to which a
shareholder of PainCare who owned the same number and kind of shares prior to such event would have been entitled upon such consolidation, merger, conveyance, conversion or exchange; and, in any such case, appropriate adjustment shall be made in the
application of the provisions herein set forth with respect to the rights and interest thereafter of the Shareholder’ rights to receive the PainCare Shares, to the end that the provisions set forth herein shall thereafter be applicable, as
nearly as reasonably possible, in relation to any shares of stock or other property thereafter deliverable upon the Shareholder’s entitlement to same. 
  
 10. SURVIVAL AND INDEMNIFICATION. 
  
 10.1 Survival of Representations and Warranties. All of the representations, warranties, covenants, and agreements including but not limited
to the restrictive covenants and the indemnification provisions contained in this Agreement are material and have been relied upon by the Parties hereto and shall survive the Closing for three and one-half (3.5) years saving those representations
warranties, covenants, and agreements set forth in Sections 4.11, 4.19, 4.20, 4.21, 4.22, 4.23, 4.26, 4.37, and 4.38 which shall survive for their applicable statute of limitations. The representations and warranties contained herein shall not be
affected by any investigation, verification or examination by any Party or by anyone on behalf of such Party. 
  
 10.2 Indemnification Provisions for the Benefit of PainCare and Subsidiary. In the event of: (a) a misrepresentation (or in the event any
third party alleges facts that, if true, would mean a misrepresentation) of any of the Shareholder’s representations and/or warranties contained in this Agreement; (b) a breach (or in the event any third party alleges facts that, if 

 true, would mean a breach) of any of the Shareholder’s covenants contained in this Agreement, or; (c) any Liability
of the Company of any nature whatsoever accrued or existing as of the Closing Date or related to actions of the Company which occurred prior to the Closing Date, which is not reflected on the Financial Statements, the Closing Date Balance Sheet, or
Section 10.2 of the Disclosure Schedule then the Shareholder agrees to indemnify PainCare and Subsidiary from and against any Adverse Consequences PainCare and Subsidiary may suffer through and after the date of the claim for indemnification
resulting from, arising out of, relating to, in the nature of, or caused by the misrepresentation or breach (or alleged breach) or non-disclosed Liability. No provision of this Agreement, including but not in any way limited to, any
“Knowledge” qualifiers or materiality standards in the representations and warranties of the Shareholder, shall have any effect on the Shareholder’s obligation to provide indemnity of any Liability arising prior to the Closing Date
which was required but omitted from the Disclosure Schedule unless such Liability was incurred on behalf of the Company by Subsidiary under the Management Agreement.. 
  
 10.3 Indemnification Provisions for the Benefit of the Shareholder. In the event of a misrepresentation or
breach (or in the event any third party alleges facts that, if true, would mean a misrepresentation or breach) of any of PainCare’s or Subsidiary’s representations, warranties, and covenants contained in this Agreement, or any Liabilities
arising after Closing from PainCare’s operation of the Company, other than medical malpractice claims, or claims for intentional wrongful acts or omissions or negligence against the Shareholder, then PainCare and Subsidiary agree to indemnify
the Shareholder from and against any Adverse Consequences the Shareholder may suffer through and after the date of the claim for indemnification resulting from, arising out of, relating to, in the nature of, or caused by the breach or
misrepresentation (or the alleged breach or misrepresentation). No provision of this Agreement, including but not in any way limited to, any “Knowledge” qualifiers or materiality standards in the representations and warranties of the
Shareholder, shall have any effect on the Shareholder’s obligation to provide indemnity of any Liability arising prior to the Closing Date which was required but omitted from the Disclosure Schedule unless such Liability was incurred on behalf
of the Company by Subsidiary under the Management Agreement. 
  
 10.4 Matters Involving Third Parties. 
  
 (a) Notification. If any third party shall notify any Party (the “Indemnified Party”) with respect to any matter (a “Third Party Claim”) which may give rise to a claim for indemnification against the other
Party (the “Indemnifying Party”) pursuant to this Section 10, then the Indemnified Party shall promptly notify the Indemnifying Party thereof in writing; provided, however, that no delay on the part of the Indemnified Party in notifying
the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless the Indemnifying Party thereby is prejudiced and then only to the extent that the Indemnifying Party is actually prejudiced. 
  
 (b) Defense by Indemnifying Party. The Indemnifying Party shall
have the right to defend the Indemnified Party against the Third Party Claim with counsel of its choice satisfactory to the Indemnified Party so long as: (i) the Indemnifying Party notifies the Indemnified Party in writing within ten (10) business
days after the Indemnified Party has given notice of the Third Party Claim that the Indemnifying Party will indemnify the Indemnified Party 

 from and against any Adverse Consequences the Indemnified Party may suffer resulting from, arising out of, relating to,
in the nature of, or caused by the Third Party Claim; (ii) the Indemnifying Party provides the Indemnified Party with evidence reasonably acceptable to the Indemnified Party that the Indemnifying Party will have the financial resources to defend
against the Third Party Claim and fulfill the Indemnifying Party’s indemnification obligations hereunder; (iii) the Third Party Claim involves only money damages and does not seek an injunction or other equitable relief; and (iv) settlement of,
or an adverse judgment with respect to, the Third Party Claim is not, in the good faith judgment of the Indemnified Party, likely to establish a precedential custom or practice adverse to the continuing business interests of the Indemnified Party
(with the understanding that with respect to costs and expenses which are directly related a precedential or continuing business interest issue of PainCare all such costs and expenses will be the responsibility of PainCare); and (v) the Indemnifying
Party conducts the defense of the Third Party Claim actively and diligently. 
  
 (c) Satisfactory Defense. So long as the Indemnifying Party is conducting the defense of the Third Party Claim in accordance with Section 10.4(b) above: (i) the Indemnified Party may retain separate
co-counsel at its sole cost and expense and participate in the defense of the Third Party Claim; (ii) the Indemnified Party will not consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim without the
prior written consent of the Indemnifying Party (not to be withheld or delayed unreasonably); and (iii) the Indemnifying Party will not consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim without
the prior written consent of the Indemnified Party (not to be withheld or delayed unreasonably) and any such settlement must include a complete release of the Indemnified Party. 
  
 (d) Conditions. In the event any of the conditions in Section 10.4(b) above is or becomes unsatisfied,
however: (i) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to, the Third Party Claim in any manner it reasonably may deem appropriate (and the Indemnified Party need not
consult with, or obtain any consent from, the Indemnifying Party in connection therewith); (ii) the Indemnifying Party will reimburse the Indemnified Party promptly and periodically for the costs of defending against the Third Party Claim (including
reasonable attorneys’ fees and expenses); and (iii) the Indemnifying Party will remain responsible for any Adverse Consequences the Indemnified Party may suffer resulting from, arising out of, relating to, in the nature of, or caused by the
Third Party Claim to the fullest extent provided in this Section 10. 
  
 10.5 Right to Set-Off. If any such cost, loss, damage, expense, liability, claim, or obligation occurs or is incurred by PainCare or Subsidiary, PainCare or Subsidiary shall have the right, after written notice to the
Shareholder, at PainCare’s or Subsidiary’s option and in addition to any other actions permitted by law, to offset the amount of any such cost, loss, damage, expense, liability, obligation or claim against amounts due from PainCare or
Subsidiary to the Shareholder, including the right to offset any post-closing payment due from PainCare or Subsidiary to the Shareholder under this Agreement or any other agreement. 
  
 10.6 Materiality. Notwithstanding any provision in this Agreement to the contrary, the indemnifying
Party’s obligation to indemnify the Indemnified Party in connection with a breach of any representation, warranty, covenant or other agreement included in this Agreement, 

 and the amount of damages to be indemnified, shall be determined without regard to any “material”,
“materiality” (or correlative meanings”) or “Material Adverse Effect” qualifications, provisions or exceptions set forth in such representation, warranty, covenant or other agreement, each of which shall be deemed to be
given for the purposes of this Section 10 as though there were no such qualifications, provisions or exceptions. 
  
 10.7 Limitation. The indemnification provisions set forth in this Section 10 shall be limited to all claims in excess of Twenty Five
Thousand and 00/100 Dollars ($25,000) (the “Threshold”). Once a claim exceeds the Threshold, if a Party is entitled to indemnification under this Section 10, such party shall recover all appropriate funds from the first dollar of damages.
Further, the indemnitors shall not be liable for any liabilities resulting from claims that are covered by any insurance policy or other indemnity or contribution agreement unless, and only to the extent that, the full limit of such insurance
policy, indemnity or contribution agreement has been exceeded. The Party entitled to indemnification shall have a duty to mitigate its damages. Notwithstanding the foregoing, the Shareholder’s obligation to indemnify under this Article 10 shall
be limited to an amount equal to $1,250,000 plus the amount of any Earnout Installment Payments paid or due pursuant to Section 3.4 of this Agreement prior to any reduction of such Installment Payments permitted under Section 3.4(g); provided
however that such cap shall not be applicable to Sections 4.2, 4.11, 4.25 and 4.36 or any intentional wrongful act or omission, and provided further, that the Shareholder shall have the option to make payment by returning to PainCare the
PainCare Shares which he received pursuant to this Agreement which shall be valued at the price at which such stock was valued under the terms of this Agreement. 
  
 11. LIQUIDATED DAMAGES; CONFIDENTIALITY. 
  
 11.1 Liquidated Damages. Shareholder agrees to pay PainCare the Liquidated Damage Penalty defined in Section
11.5(b) below if Shareholder during the Formula Periods, and for a period of two (2) years thereafter, except on behalf of PainCare, under any circumstances, with or without compensation, individually or as an operator, investor, shareholder,
partner, director, employee, independent contractor, consultant, manager, advisor or in any other capacity whatsoever, provides pain management and physical medicine and rehabilitation medical services or serves as a medical director in connection
with pain management and physical medicine and rehabilitation at any location within 100 miles of 121 West Century Avenue, Bismarck, North Dakota. 
  
 11.2 Solicitation. Shareholder further agrees to pay PainCare the Liquidated Damage Penalty defined in Section 11.5.(b) below if Shareholder
during the Formula Periods, and for a period of two (2) years thereafter, except on behalf of PainCare or the New PC, shall: 
  
 11.2.1 Solicit referrals from physicians who refer to PainCare or the New PC; or 
  
 11.2.2 Directly or indirectly, solicit, on behalf of himself or on behalf of or in conjunction with others, any patient who
has been treated by PainCare or the New PC (whether or not through Shareholder); provided, however, Shareholder may accept such patients if unsolicited; or 
  
 11.2.3 Solicit any person who was an employee of PainCare, the Company or the New PC to become employed by Shareholder or any other person with whom
Shareholder may become affiliated; or 

 11.2.4 Solicit or engage in the solicitation of, or serve or accept any business from patients, insurance
companies, managed care plans, employers or other customers of the business conducted by PainCare or the Surviving Corporation for services competitive with those of PainCare or Subsidiary, PainCare’s and Subsidiary’s successors and
assigns, or PainCare’s and Subsidiary’s Affiliates; 
  
 11.2.5 Request, induce or advise any patients, insurance companies, managed care plans, suppliers, vendors, employers or other customers of the business conducted by PainCare or Subsidiary, or PainCare’s or Subsidiary’s Affiliates
to withdraw, curtail or cancel their business or other relationships with PainCare or Subsidiary, or assist, induce, help or join any other person or entity in doing any of the above activities. 
  
 11.3 No Running of Provisions During Breach. If Shareholder
violates such provision and PainCare brings legal action for relief, PainCare shall not, as a result of the time involved in obtaining the relief, be deprived of the benefit of the full period of such provision. Accordingly, for any time period that
Shareholder is in violation of the provisions set forth in this Section 11, such time period shall not be included in calculating any such time period described in this Section 11. 
  
 11.4 Duration and Geographical Limits. If it shall be determined that the duration or geographical limit of
any provision contained in this Section 11 is unenforceable, it is the intention of the parties that the provisions set forth herein shall not thereby be terminated, but shall be deemed amended to the extent required to render it valid and
enforceable, such amendment to apply only with respect to the operation of this Section 11. 
  
 11.5 Reasonable. 
  
 (a) The Shareholder acknowledges that (i) the provisions contained in this Section 11 are a reasonable and bear a reasonable and fair relationship to the probable damages that PainCare and PainCare would incur; (ii) are a necessary
protection of the legitimate interests of PainCare; and (ii) the damages that would be suffered by PainCare in the event of a breach of this Section 11 by Shareholder would be difficult to ascertain with any certainty. 
  
 (b) Accordingly, as Liquidated Damages, and not as a penalty, in the event of
a violation by Shareholder of the provisions of Section 11.1, 11.2 or any of the subsections thereunder, Shareholder shall pay PainCare, liquidated damages equal to $1,250,000 plus the amount of any Earnout Installment Payments paid or due pursuant
to Section 3.4 of this Agreement prior to any reduction of such Installment Payments permitted under Section 3.4(g); provided however that the Shareholder shall have the option to make payment by returning to PainCare the PainCare Shares
which he received pursuant to this Agreement which shall be valued at the price at which such stock was valued under the terms of this Agreement. 
  
 (c) In addition to the foregoing, a violation by Shareholder of any of the provisions of this Section 11 shall trigger section 4.14 of the Management
Agreement. 

 11.6 Third-Party Beneficiaries. All successors and assigns of PainCare, Subsidiary, all
Affiliates of PainCare and Subsidiary, and all successors and assigns of such Affiliates are third-party beneficiaries of the restrictive covenants contained in this Section 11 and the provisions of this Section 11 are intended for the benefit of,
and may be enforced by, PainCare’s and Subsidiary’s successors and assigns and PainCare’s and Subsidiary’s Affiliates and such Affiliates’ successors and assigns. 
  
 11.7 Defenses. The existence of any claim or cause of action by the Shareholder against PainCare or
Subsidiary, whether predicated upon this Agreement or otherwise, shall not constitute a defense to the enforcement by PainCare, Subsidiary, or any of PainCare’s or Subsidiary’s successors and assigns or Affiliates and such Affiliates’
successors and assigns, but shall be litigated separately. The provisions of this Section 11 shall survive the termination of this Agreement. 
  
 11.8 Blue Pencil Doctrine. The covenants set forth in this Section 11 are severable and separate, and the unenforceability of any specific
covenant shall not affect the provisions of any other covenant. Moreover, in the event any court of competent jurisdiction shall determine that the scope, time or territorial restrictions set forth are unreasonable, then it is the intention of the
parties that such restrictions be enforced to the fullest extent which the court deems reasonable, and the Agreement shall thereby be reformed. 
  
 11.9 Confidentiality, Press Releases, and Public Announcements. 
  
 (a) No Party shall issue any press release or make any public announcement relating to the subject matter of this Agreement
without the prior written approval of the other Parties. 
  
 (b)
The Parties covenant and agree that from and after the Execution Date, neither of the Parties nor their Affiliates (to the extent any such Affiliate has received Confidential Information as defined below or Trade Secrets, as defined below) shall
disclose, divulge, furnish or make accessible to anyone any Confidential Information or Trade Secrets, or in any way use any Confidential Information or Trade Secrets in the conduct of any business; provided, however, that nothing in this Section
11.9 will prohibit the disclosure of any Confidential Information or Trade Secrets which is required to be disclosed by a Party or any of its or his Affiliates in connection with any court action or any proceeding before any authority.
Notwithstanding the foregoing, in the case of a disclosure contemplated by this Section 11.9, no disclosure shall be made until the disclosing Party shall give notice to the non-disclosing Party of the intention to disclose such Confidential
Information or Trade Secrets so that the non-disclosing Party may contest the need for disclosure, and the disclosing Party will cooperate (and will cause its or his Affiliates and their respective representatives to cooperate) with the
non-disclosing in connection with any such proceeding. Notwithstanding any provision of this Agreement which may be to the contrary, the foregoing provisions restricting the use of Confidential Information and Trade Secrets shall survive the Closing
for the time period equal to five (5) years from the Execution Date. For the purpose of this Agreement, the term “Confidential Information” shall mean all records, files, reports, protocols, policies, manuals, databases, processes,
procedures, computer systems, materials and other documents pertaining to the operations of a Party and the term “Trade Secrets” shall mean information, including a 

 
formula, pattern, compilation, program, device, method, technique, or process that: (i) derives independent economic value, actual or potential, from not
being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use; and (ii) is the subject of efforts that are reasonable under the circumstances to maintain its
secrecy. 
  
 11.10 Conduct of Business. From the
date hereof through the Closing, the Shareholder shall, except as contemplated by this Agreement, or as consented to by PainCare in writing, cause the Company to be operated in the ordinary course and in accordance with past practice and will not
take any action inconsistent with this Agreement or with the consummation of the Closing. Without limiting the generality of the foregoing, the Company shall not, and, with respect to the Company, the Shareholder shall not, except as specifically
contemplated by this Agreement, as set forth in Section 11.10 of the Disclosure Schedule, or as consented to by PainCare in writing: 
  
 (a) change or amend the organizational documents of the Company; 
  

(b) enter into, extend, materially modify, terminate or renew any lease or any contract, except modifications, extensions or renewals of contracts in
the ordinary course of business or as contemplated by this Agreement; 
  
 (c) sell, assign, transfer, convey, lease, mortgage, pledge or otherwise dispose of or encumber any of the assets or any interests therein of the Company except in the ordinary course of business and, without limiting the generality of the
foregoing, the Company will maintain, dispose of, and sell inventory consistent with past practices; 
  
 (d) incur any liability for indebtedness for borrowed money, guarantee the obligations of others, indemnify or agree to indemnify others or, except in the
ordinary course of business, incur any other liability; 
  
 (e)
take any action with respect to the grant of any bonus, severance or termination pay (otherwise than pursuant to policies or agreements of the Company in effect on the date hereof that are described in the Disclosure Schedule) or with respect to any
increase of benefits payable under its severance or termination pay policies or agreements in effect on the date hereof or increase in any manner the compensation or fringe benefits of any employee of the Company or pay, any benefit not required by
any existing Employee Plan or policy; 
  
 (f) make any change in
the key management structure of the Company, including, without limitation, the hiring of additional officers or the termination of existing officers; 
  
 (g) adopt, enter into or amend any Employee Plan, agreement (including, without limitation, any collective bargaining or employment agreement), trust,
fund or other arrangement for the benefit or welfare of any employee, except for any such amendment as may be required to comply with applicable regulations; 
  
 (h) fail to maintain all Employee Plans in accordance with applicable Regulations; 

 (i) acquire by merger or consolidation with, or merge or consolidate with, or purchase substantially all
of the assets of, or otherwise acquire any material assets or business of, any corporation, partnership, association or other business organization or division thereof or acquire any subsidiary; 
  
 (j) willingly allow or permit to be done any act by which any of the
insurance policies of the Company or Shareholder may be suspended, impaired or canceled; 
  
 (k) enter into, renew, modify or revise any agreement or transaction relating to the Company with any of its or their Affiliates except as contemplated by this Agreement; 
  
 (l) fail to maintain the assets of the Company in substantially their current
state of repair, excepting normal wear and tear, or fail to replace (consistent with the Company’s past practice) inoperable, worn-out or obsolete or destroyed assets; 
  
 (m) make any loans or advances relating to the Company to any partnership, firm, individual, or corporation, except for
expenses incurred in the ordinary course of business consistent with past practice; 
  
 (n) fail to comply in all material respects with all laws and regulations applicable to the Company; 
  
 (o) intentionally do any other act which would cause any representation or warranty of the Company or the Shareholder in this Agreement to be or become
untrue, or any covenant in this Agreement to be breached, in any material respect; 
  
 (p) fail to use reasonable efforts consistent with past business practice to (i) maintain the Company so that the services of its officers, employees, consultants and agents will remain available to it on and after
the Closing Date, (ii) maintain existing relationships with suppliers, patients, customers and others having business dealings with the Company and (iii) otherwise preserve the goodwill of the business of the Company so that such relationships and
goodwill will be preserved on and after the Closing Date; 
  
 (q)
enter into any agreement, or otherwise become obligated, to do any action prohibited hereunder; 
  
 (r) except as provided herein, declare, set aside for payment, or pay any dividend or distribution in respect of any capital stock of the Company, redeem,
purchase or otherwise acquire any of the Company’s equity securities; or otherwise transfer any of the assets of the Company to or on behalf of any Shareholder of the Company or any Affiliate of the Company, including, without limitation, any
payment of principal of or interest on any debt owed to any of the foregoing or any payment of a bonus, fee or other payment to any of the foregoing as an employee of the Company; or 
  
 (t) fail to comply with all applicable filing, payment, withholding, collection and record retention obligations under all
applicable federal, state, local or foreign Tax laws. 

 11.11 No Third-Party Beneficiaries. Other than with respect to the restrictive covenants
set forth in Section 11, this Agreement shall not confer any rights or remedies upon any Person other than the Parties and their respective successors and permitted assigns. 
  
 12. MISCELLANEOUS. 
  
 12.1 Entire Agreement. This Agreement (including the documents referred to herein) constitutes the entire agreement between the Parties and
supersedes any prior understandings, agreements, or representations by or between the Parties, written or oral, to the extent they related in any way to the subject matter hereof. 
  
 12.2 Succession and Assignment. This Agreement shall be binding upon and inure to the benefit of the Parties
named herein and their respective successors, assigns, distributees, heirs, and grantors of any revocable trusts of a Party hereto. No Party may assign either this Agreement or any of its or his rights, interests, or obligations hereunder without
the prior written approval of the other Parties; provided, however, PainCare and Subsidiary, may, without the prior consent of the other Party, assign this Agreement to their Affiliates. 
  
 12.3 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed
an original but all of which together will constitute one and the same instrument. 
  
 12.4 Headings. The section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. 
  
 12.5 Notices. All notices, requests, demands, claims, and other
communications hereunder will be in writing. Any notice, request, demand, claim, or other communication hereunder shall be deemed duly given: (a) upon receipt if it is sent by facsimile, (b) the next business day if sent by reputable overnight
courier, or (c) five (5) days after mailing if by certified mail return receipt requested, postage prepaid, and addressed or otherwise sent to the intended recipient as set forth below: 
  

	 If to PainCare
	 	 
	 or Subsidiary:
	 	PainCare Holdings, Inc.
	 	 	37 North Orange Avenue
	 	 	Suite 500
	 	 	Orlando, Florida 32801
	 	 	Attention: President
		
	 If to the Shareholder:
	 	Michael P. Martire, M.D.
	 	 	121 W. Century Ave.
	 	 	Bismarck, ND 58501
		
	 If to the Company:
	 	Spine and Pain Center, Inc.
	 	 	121 W. Century Ave.
	 	 	Bismarck, ND 58501

	 With a copy in each case to:
	 	Douglas Watson Lubic, Esq.
	 	 	Meridian Center 1
	 	 	Two Industrial Way West
	 	 	Eatontown, NJ 07724-2265

  
 Any Party may send any notice,
request, demand, claim, or other communication hereunder to the intended recipient at the address or facsimile number set forth above using any other means (including personal delivery, messenger service, ordinary mail, or electronic mail), but no
such notice, request, demand, claim, or other communication shall be deemed to have been duly given unless and until it actually is received by the intended recipient. Any party may change the address or facsimile number to which notices, requests,
demands, claims, and other communications hereunder are to be delivered by giving the other Party notice in the manner herein set forth. 
  
 12.6 Governing Law; Jurisdiction; Attorney’s Fees. This Agreement, and all proceedings hereunder, shall be governed by and construed in
accordance with the domestic laws of the State of Florida without giving effect to any choice or conflict of law provision or rule (either of the State of North Dakota or any other jurisdiction) that would cause the application of the laws of any
jurisdiction other than the State of Florida. In the event of any suit under this Agreement or otherwise between the parties hereto, the prevailing Party shall be entitled to all reasonable attorney’s fees and costs, including allocated costs
of in-house counsel, to be included in any judgment recovered. In addition, the prevailing Party shall be entitled to recover reasonable attorney’s fees and costs, including allocated costs of in-house counsel, incurred in enforcing any
judgment arising from a suit under this Agreement. This post-judgment attorney’s fees and costs provision shall be severable from the other provisions of this Agreement and shall survive any judgment on such suit and is not to be deemed merged
into the judgment. 
  
 12.7 Amendments and Waivers.
No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed by the Parties. No waiver by any Party of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional
or not, shall be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence and all waivers must be
in writing, signed by the waiving Party, to be effective. 
  
 12.8
Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or
enforceability of the offending term or provision in any other situation or in any other jurisdiction. 
  
 12.9 Expenses. Except as set forth herein, Shareholder shall bear and be responsible and shall pay for all costs and expenses (including,
but not limited to, legal and accounting fees and expenses) incurred by Shareholder, the Company and the New PC in connection with this Agreement and the transactions contemplated hereby. Notwithstanding the foregoing, PainCare agrees (i) to pay at
Closing Shareholder or if directed by Shareholder, his legal counsel, $20,000 as reimbursement for legal costs incurred by Shareholder with respect to this transaction, and (ii) to be solely responsible for the cost of the GAAP Financial Statements
prepared in connection with this Agreement. 

 12.10 Further Assurances. Each Party shall, at the reasonable request of any other Party
hereto, execute and deliver to such other Party all such further instruments, assignments, assurances and other documents, and take such actions as such other Party may reasonably request in connection with the carrying out the terms and provisions
of this Agreement. 
  
 12.11 Construction. Any
reference to any federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. The word “including” shall mean including without
limitation. Nothing in the Disclosure Schedule shall be deemed adequate to disclose an exception to a representation or warranty made herein, unless the Disclosure Schedule identifies the exception with reasonable particularity. The Parties intend
that each representation, warranty, and covenant contained herein shall have independent significance. If any Party has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists another
representation, warranty, or covenant relating to the same subject matter (regardless of the relative levels of specificity) which the Party has not breached shall not detract from nor mitigate the fact that the Party is in breach of the first
representation, warranty, or covenant. 
  
 12.12
Survival. All of the representations, warranties, covenants and agreements including but not limited to Articles VI and VII made by the Parties in this Agreement or pursuant hereto in any certificate, instrument or document shall
survive the consummation of the transactions described herein shall survive for all applicable statute of limitations, and may be fully and completely relied upon by Sellers and the Acquiring Companies, as the case may be, notwithstanding any
investigation heretofore or hereafter made by any of them or on behalf of any of them, and shall not be deemed merged into any instruments or agreements delivered at Closing or thereafter. 
  
 12.13 Incorporation of Exhibits and Schedules. The exhibits and
schedules (including the Disclosure Schedule) identified in this Agreement and the recitals first set forth above are incorporated herein by reference and made a part hereof. 
  
 12.14 Submission to Jurisdiction. With respect to any legal proceeding brought by PainCare which arises out of
or relates to this Agreement or the transactions contemplated hereby, exclusive jurisdiction and venue with respect to such matter shall lie in any state or federal court within Burleigh County, ND. With respect to any legal proceeding brought by
the Shareholder or the Company which arises out of or relates to this Agreement or the transactions contemplated hereby, exclusive jurisdiction and venue with respect to such matter shall lie in any state or federal court within Orange County, FL.
Each party to this Agreement hereby irrevocably waives, to the fullest extent permitted by law, any objections which it may now or hereafter have to the laying of the venue of any such proceeding brought in such a court and any claim that any such
proceeding brought in such a court has been brought in an inconvenient forum. 

 13. DISPUTE RESOLUTION 
  

13.1 Dispute Resolution. 
  
 13.1.1 General. In the event of any dispute, difference or question arising between the Parties in connection with this Agreement, the
construction thereof, or the rights, duties or liabilities of either Party, and which dispute cannot be amicably resolved by the good faith efforts of the Parties, then such dispute shall (i) be resolved by non-binding arbitration conducted in the
manner set forth in Section 13.1.2, and (ii) in the event that such dispute is not amicably resolved by such non-binding arbitration, then the Parties may seek to enforce their rights in the courts of competent jurisdiction. 
  
 16.1.2 Arbitration. In the event of the occurrence of a dispute
which cannot be amicably resolved by the good faith efforts of the Parties, either Party may, by notice to the other Party, commence a non-binding arbitration to resolve such dispute by providing written notice to the other Party, which notice (a
“Arbitration Notice”) shall inform the other Party of such dispute and the issues to be resolved and shall contain a list of three (3) recommended individuals to serve as the arbiters. Within ten (10) business days after the receipt of
such Arbitration Notice, the other Party shall respond by written notice to the Party initiating arbitration, which notice shall contain a list of three (3) recommended individuals to serve as the arbiters and which may add additional issues to be
resolved. The recommended arbiters shall be individuals with experience in the healthcare industry and shall not be an employee, director, shareholder or agent of either Party or of an Affiliate or subsidiary of either Party, or otherwise involved
(whether by contract or otherwise) in the affairs of either Party. If, within twenty (20) business days after receipt of such Arbitration Notice, the Parties shall have been unable to mutually agree upon an individual to serve as an arbiter, then
the Parties may seek to enforce their rights in the Courts of competent jurisdiction. If, within twenty (20) business days after receipt of such Arbitration Notice, the Parties shall have mutually agreed upon an individual to serve as an arbiter,
then the arbiter shall conduct a arbitration in an effort to resolve such dispute as follows: (i) Within thirty (30) business days after selection, the arbiter shall hold a hearing to resolve each of the issues identified by the Parties. Each Party
shall be represented at the hearing by up to two (2) employees of such Party, one of whom is an officer of such Party, and may be represented by counsel. The hearing shall be held in a mutually agreeable location. No discovery will be conducted,
unless the Parties otherwise mutually agree. (ii) At least ten (10) business days prior to the date set for the hearing, each Party shall submit to the other Party and the arbiter a proposed ruling on each issue to be resolved, which writing (A)
may, in addition to containing the proposed rulings, contain arguments or analyses of the facts or issues and (B) shall be limited to not more than twenty (20) pages. (iii) Each Party shall be entitled to no more than three (3) hours of hearing time
to present oral testimony. The oral testimony of both Parties shall be presented during the same calendar day. Such time limitation shall include any direct, cross or rebuttal testimony, but such time limitation shall only be charged against the
Party conducting such direct, cross or rebuttal testimony. It shall be the responsibility of the arbiter to determine whether the Parties have had the presentation time to which they are entitled. (iv) At the hearing, the arbiter shall attempt to
resolve each issue in dispute between the Parties. If the arbiter shall be unable to resolve any issue, the arbiter shall provide the Parties with the arbiter’s non-binding ruling on each such issue. The arbiter shall, in rendering his
decision, apply the substantive law of the State of Florida, without giving effect to its principles of conflicts of law, and without giving effect to any rules or laws relating to arbitration. The arbitration proceeding shall be confidential.
Except as required by law, no Party shall make (or instruct the arbiter to make) any 

 
public announcement with respect to the proceedings or rulings of the arbiter without the prior written consent of each other Party. The existence of any
dispute submitted to arbitration, and the rulings of the arbiter, shall be kept in confidence by the Parties and the arbiter, except as required by applicable law. (vi) Each Party shall pay its own costs (including, without limitation,
attorney’s fees) and expenses in connection with such arbitration. The fees and expenses of the arbiter shall be shared equally by the Parties. 
  
 [SIGNATURES APPEAR ON NEXT PAGE] 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date first above
written. 
  

	PAINCARE:
	
	PAINCARE HOLDINGS, INC., a Florida corporation
		
	 By:
	 	 /s/ Randy Lubinsky

	 Print:
	 	 Randy Lubinsky

	 Its:
	 	 Chief Executive Officer

	
	ACQUISITION:
	
	PAINCARE ACQUISITION COMPANY VI, INC., a Florida corporation
		
	 By:
	 	 /s/ Randy Lubinsky

	 Print:
	 	 Randy Lubinsky

	 Its:
	 	 Chief Executive Officer

	
	COMPANY:
	
	SPINE AND PAIN CENTER, INC.
		
	 By:
	 	 /s/ Michael P. Martire, M.D.

	 Print:
	 	 Michael P. Martire, M.D.

	 Its:
	 	 President

	
	SHAREHOLDER:
	
	 /s/ Michael P. Martire, M.D.

	 Michael P. Martire, M.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}]]